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Abstract
The telemedicine intervention in chronic disease management
promises to involve patients in their own care, provides continuous
monitoring by their healthcare providers, identifies early symptoms,
and responds promptly to exacerbations in their illnesses. This review
set out to establish the evidence from the available literature on the
impact of telemedicine for the management of three chronic diseases:
congestive heart failure, stroke, and chronic obstructive pulmonary
disease. By design, the review focuses on a limited set of represen-
tative chronic diseases because of their current and increasing im-
portance relative to their prevalence, associated morbidity, mortality,
and cost. Furthermore, these three diseases are amenable to timely
interventions and secondary prevention through telemonitoring. The
preponderance of evidence from studies using rigorous research
methods points to beneficial results from telemonitoring in its various
manifestations, albeit with a few exceptions. Generally, the bene-
fits include reductions in use of service: hospital admissions/re-
admissions, length of hospital stay, and emergency department visits
typically declined. It is important that there often were reductions in
mortality. Few studies reported neutral or mixed findings.
Key words: telemedicine, telehealth, telemonitoring, evidence,
chronic disease, telestroke, telepulmonology
Introduction and Overview
T
his report provides an analysis of the extant scientific evi-
dence concerning the impact of telemedicine on three critical
issues in healthcare—access, quality, and cost—with a focus on
chronic diseasemanagement. We begin with a cursory review
of these issues in the United States, followed by a brief discussion of the
history and promise of telemedicine in addressing them. Subsequently,
the focus turns to a review of the available evidence from rigorous
empirical studies regarding the effects of telemedicine in the man-
agement of chronic diseases, specifically, congestive heart failure
(CHF), stroke, and chronic obstructive pulmonary disease (COPD). Fi-
nally, we turn our attention to the economics of telemedicine.
The reasons for our focus on the management of chronic diseases
are twofold. (1) The vast number of published research articles dealing
with the wide variety of telemedicine applications and the need to reach
a conclusion regarding the available evidence render an all-inclusive
approach rather impractical. More important is that a voluminous report
may not add a commensurate amount of information that would alter
the conclusions reached by a focused approach. (2) Chronic disease is
highly prevalent, is predicted to increase substantially in the foreseeable
future, and is costly and potentially manageable via telemedicine.
For convenience and clarity, we use ‘‘telemedicine’’ as an inclusive
term throughout this report to refer to the delivery of healthcare via
information and communication technology (ICT). As such, it in-
cludes ‘‘telehealth,’’ ‘‘e-health,’’ ‘‘mobile health’’ (m-health), and
‘‘connected health.’’
DOI: 10.1089/tmj.2014.9981 ª MARY ANN L I EBERT , I NC .  VOL. 20 NO. 9  SEPTEMBER 2014 TELEMEDICINE and e-HEALTH 769
Beyond the Patient Protection and Affordable Care Act, a wide range
of reforms is necessary to address intransigent problems in healthcare
delivery in the United States and worldwide. These include inequities in
the availability and access to health services for significant segments of
the population, inefficiencies in the prevailing modes of healthcare
delivery and financing, uneven distribution of quality, escalating cost,
and the prevalence of adverse lifestyles that tend to exacerbate these
problems. Concurrently, dramatic advances in the capabilities of ICT
and its expanding vital role in all sectors of modern society present a
compelling case for a thorough examination of the underlying evi-
dence and its appropriate deployment in healthcare. Indeed, the use of
ICT in healthcare lags behind in comparison with other sectors in so-
ciety, including commerce, education, transportation, entertainment,
and finance. It is time to examine the empirical evidence regarding the
effectiveness and efficiency of ICT in the health sector for lessons
learned and for optimal deployment of these systems.
The Differentials in Access, Quality, and Cost
Differences in access to care reflect economic, geographic, and
functional as well as social, cultural, and psychological factors.
Whereas the Affordable Care Act was implemented mostly to relieve
the economic burden of medical care access for those currently
without insurance or underinsured, there remain sizeable segments
of the population (including the insured) with limited access to care
by virtue of where they live and work or having chronic health
problems that require continual care and attention. Residents of rural
and isolated areas are frequently faced with limitedmedical resources
within reasonable driving distance/time, whereas many residents of
the inner city have limited access to medical resources for economic
reasons. It is important that a large and growing segment of the
population suffers from chronic diseases and can benefit from im-
proved spatial–temporal access to health resources while trying to
manage their health as best they can in their own homes.1
Concern with quality dates backmore than a century. For example,
in 1847, a resolution was passed at the first national meeting of the
American Medical Association to determine the quality of ‘‘practi-
tioners of medicine in respective states..’’2 A subsequent report3
from Virginia pointed out an alarming number of practitioners ‘‘who
practice without any authority whatever’’ and those ‘‘who do not
pretend to have devoted one hour to the study of the profession.’’
However, the drastic reforms in medical education and professional
licensing at the turn of the 20th century had the unintended effect of
decreasing physician supply substantially, especially in rural areas
and among minority populations. We have yet to fully rectify that
problem. It is interesting that, at the time, some4,5 have suggested that
the ‘‘alleged shortage’’ of physicians would soon be resolved by a new
technology.the automobile. This has not materialized because the
problems were vastly more complex than mere transportation.
Differences in the distribution of good-quality healthcare largely
reflect the discrepancy between the locations of medical resources at
various levels of expertise vis-a`-vis the location of patients who need
their care. Physicians tend to locate in urban areas because the educa-
tional systemreinforces specialization, and the availability of advanced
technology at tertiary-care centers acts as a further attraction. A long-
standing consensus among students of the field points to an optimal
ratioof1:1 for specialist togeneralist.6 Instead, it isabout3:1. In2012, in
total, 878,194 physicians with an active license were practicing in the
United States.7 Of these, 657,208 (76.5%) were certified by a specialty
board, and 216,352 (23.5%)were not. Formany, specializationnarrows
the scopeofpractice to specificbodyorgans, diseases, or ageandgender
groups, hence the tendency to locate specialty practices in large urban
areas with large populations from which to draw their patients.
Concern with medical care cost inflation (typically expressed as a
percentage of gross domestic product) dates back to the 1960s, when
it was around 5%. It is now close to 18%. As many have observed, the
health system in the United States is on a nonsustainable course
unless significant changes are introduced to deliver care more effi-
ciently and effectively. Indeed, without appropriate innovative
structural changes, we may soon be faced with the dilemma of either
maintaining substantial inequities in access to care by virtue of
residential location, socioeconomic status, and health need or not
being able to afford the system we have. The basic problem was
brought about by a combination of factors, including the following:
1. The demographic composition of the population is changing. A
long-term trend of low birth rates and longer life expectancy
has resulted in a larger proportion of the population in older
age groups. This segment of the population experiences more
chronic illness, which entails increased costs.
2. Advances in medical science, technology, and interventions
have led to the development of more sophisticated diagnostic
tools, life-saving interventions, medications, and devices. Al-
though contributing to improved health status, this has fueled
inflationary trends in healthcare.
3. Advances in ICT have heightened public awareness and health
sophistication (with greater public awareness of behavioral
risk factors, ready access to sources of health information, and
an active and extensive lay referral system), thereby increasing
demand for medical care.
4. Finally, system fragmentation, discontinuities in patient care, and
serious inefficiencies in the financing and delivery of care as well
as the prevalence of unhealthy lifestyles have all exacerbated the
problem, especially among those suffering from chronic illness.
Hence, the focus of this article is on the capabilities of health ICT not
only in extending the reach of clinical resources to serve a widely
dispersed and underserved patient population, but, more impor-
tantly, in improving the efficiency, effectiveness, coordination, and
continuity of care with active patient participation in the manage-
ment of chronic illness.
As a prelude to the discussion of the integral role of telemedicine in
modern healthcare delivery in general and chronic disease man-
agement in particular, we begin with a brief account of telemedicine’s
long history. This demonstrates the centrality of long distance
communication in medicine and in human experience. At the same
time, it provides a stark reminder of the remarkable and steady
progress in the underlying technology of telemedicine.
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Brief History of Telemedicine
The use of long distance communications for medical purposes
extends into antiquity. (For a more complete history, see Bashshur
and Shannon.8) For example, among aboriginal peoples of Australia
‘‘message sticks’’ carried by runners, sometimes more than 70 miles,
brought information pertaining to tribal gatherings (friendly and
hostile), disease and deaths.9 Medicine ‘‘in absentia’’ was practiced in
the 17th century common era as patients sent urine samples to distant
physicians who, in turn, provided diagnoses based on uroscopy
charts patterned after those used by the ancient Greeks.10 In return,
local physicians and their patients received a ‘‘prescription-by-post’’
containing detailed instructions on regimen.11 Our major focus here,
however, is on the use of electronic communication providing
medical care at a distance. We begin, therefore, with the telegraph.
During the American Civil War, the need to identify the location and
movement of troops led to the development of the Signal Corps, which
relied heavily on the telegraph. The Corps was established in 1862 and
became operational in 1863 under the direction ofMajor Albert Myer, a
surgeon and medical officer in the Union Army. In addition to the
original intent of the Corps, he used the telegraph to request medical
supplies and coordinate the transport of patients.12 Anecdotal justifi-
cation for use of the telephone in distant diagnosis can be found in an
early report in The Lancet in 1879.13 Amother, convinced her baby had
the ‘‘croup,’’ called the infant’s grandmother.who, in turn telephoned
the family doctor at midnight ‘‘to tell him the terrible news.’’ The
physician telephoned the mother and asked her to ‘‘lift the child to the
telephone and letme hear it cough.’’ Subsequently, he declared: ‘‘That is
not the croup,’’ advising the mother, child, and grandmother to stay in
bed, whereupon ‘‘the trio settled down happily for the night.’’
Willem Einthoven (1860–1927), a Dutch physician and inventor,
demonstrated the use of the telephone for diagnostic purposes in 1905.
He combined his improved galvanometer with the emerging telephone
technology to transmit heart sounds froma hospital to his laboratory—a
distance of 0.9 mile—and referred to the product as a ‘‘telecardiogram.’’
Einthoven is credited with the first use of the prefix ‘‘tele’’ in a medical
context that appeared in an article published in 1906.14
In 1910, British (but Chicago-born) Sidney G. Brown discovered a
diagnostic function for the telephone while looking for a solution to
the rapid degradation of telephone signals over distances ofmore than
20 miles. He developed a ‘‘repeater, amplifier, and receivers allowing
clear articulation (of telephone) transmission of up to and more than
fifty miles.’’15 Subsequently, he demonstrated his invention at several
hospitals in London. It is important that Brown concluded ‘‘this trial
proved that it is now possible for a specialist, say, in London, to
examine a patient, say, in the country, stethoscopically, and to arrive
at a correct diagnosis.’’15 Also in 1910, in New York, cardiologists
Walter James and Horatio Williams described their experience with
the transmission of electrocardiograms (ECGs) for a wide range of
cardiac issues, including hypertrophy, ectopics, and fibrillations: ‘‘We
have the wards of PresbyterianHospital connectedwith the laboratory
by a system of wiring which permits the taking of any patient’s
electrocardiogram without removing him from his bed.’’16
In 1920, the concept of using telecommunications for medical pur-
poses was put into practice in Norway.17 Bergen’s Haukeland Hospital
established a radio service to provide clinical support for ships at sea,
including urgent surgical operations.18 By the end of the 1920s, several
Western European countries with substantial maritime operations had
established similar radio services to provide medical consultation, di-
agnosis, and clinical and surgicalmentoring for ships at sea.19 The Italian
maritime program, begun in 1935, continues to be operational today.
In 1948, Austin Cooley, a telecommunications inventor who played
a major role in the development of the facsimile machine, developed a
system for ‘‘long-distance roentgenographic facsimile via commercial
telephone wires or radio.’’ In 1950, Gershon-Cohen, a radiologist, and
Cooley20 described their experience transmitting X-ray images over
wire or radio circuits, referring to this system as ‘‘‘telognosis’.a
‘condensation’ of three terms, to wit, teleo, roentgen, and diagnosis.’’
They used the system routinely over a distance of some 28 miles. In
one instance,20 Philadelphia physicians at Albert Einstein Medical
Center successfully identified a large bowel obstruction of a ‘‘promi-
nent’’ citizen in Chester County, which was treated locally. This was
followed byAlbert Jutras, a radiologist inMontreal who demonstrated
in a 1957 publication the feasibility of transmitting radiographic
images via coaxial cable between the Hotel-Dieu and the Jean-Talon
Hospitals, about 5 miles apart; Jutras and Duckett21 presaged ‘‘asyn-
chronous’’ telemedicine by suggesting ‘‘the use of video tapes would
be an indispensable tool adjunct.’’ Jutras introduced the term ‘‘tele-
fluoroscopy’’ for the transmission of radiologic images via coaxial
cable. Both Jutras’ term and that of Cooley and Gershon-Cohen did
not achieve much ‘‘traction’’ and were soon forgotten. At about the
same time at the University of Nebraska, Wittson and Dutton22 ex-
perimented with the use of bidirectional closed-circuit television in
psychiatry for medical education and training and later to conduct
group therapy sessions ‘‘at a distance.’’ Telemedicine came of age
during the 1970s. The first prototype telemedicine program was es-
tablished in 1968 in Boston, linking the Medical Station at Logan
International Airport with Massachusetts General Hospital. This was
followed by several exploratory projects funded by the federal gov-
ernment (including the Department of Health, Education andWelfare,
the National Science Foundation, the National Library of Medicine,
the Office of Economic Opportunity, and the Regional Medical Pro-
gram) as well as the National Aeronautics and Space Administration’s
terrestrial telemedicine test beds in Alaska and Arizona and its use of
telemetry in early human space flight.
Today, telemedicine can be found in every state of the union and
almost every country in the world. However, in the United States it
continues to be encumbered by policies that are no longer functional,
especially those related to the rules and requirements for reim-
bursement and interstate licensure and practice.
Prerequisites for Definitive Evaluation
of Telemedicine
Despite voluminous research in this field, investigators have yet to
reach consensus on a set of requirements for valid evaluation in
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telemedicine as well as healthcare in general. (For a detailed discus-
sion of these issues, see Bashshur et al.23) Certainly, choice of study
design and sample design, measurement tools, and analytic meth-
odology are central. However, there are also variations in the settings,
choice of study populations (in terms of illness severity and other
parameters), and program implementation that may have significant
implications for interpreting the findings. These can be grouped into
three major issues: fidelity, maturation, and bundling. The issue of
‘‘fidelity’’ pertains to the intervention itself. A valid evaluation de-
pends on assessing the intervention in a ‘‘full fidelity mode,’’ that is, at
an appropriate setting with the optimal level of strength and integrity.
Telemedicine interventions vary by clinical application (type and
range of services offered), technological configuration (telephone,
video, cameras, scopes, sensors, and other devices; automated and
manual), transmission mode (synchronous and/or asynchronous),
and health manpower mix (physicians, nurses, therapists, managers,
and engineers), as well as organizational structures and protocols. All
have implications on what hypotheses can or cannot be demonstrated
in a given research study. Without fidelity, we may not be able to
attribute outcomes to interventions in any definitive manner. The
second prerequisite is ‘‘maturation.’’ This pertains to the timing of the
implementation/adoption process and the point in the maturation
process at which the assessment takes place. Included is the function
of the ‘‘learning curve’’ necessary for the integration of personnel,
technology, and patients to achievemaximumefficiency. It is difficult
to determine the point along the learning curve of a program’s road to
maturity. Additionally, telemedicine has evolved as an ‘‘innovation
bundle’’ consisting of various configurations of technology, human
resources, service populations, clinical applications, and organiza-
tional structures. Each of these components may have independent
effects on access, quality, and/or cost. However, it is often difficult to
separate the specific effects of each component in a scientific study
because the components are rarely taken into account in the design of
studies, and the statistical power associated with small samples does
not usually permit reliable subgroup analysis.
Telemedicine and Chronic Disease Management
The justification for the wider deployment of telemedicine stems
from an ever-expanding and complex body of empirical evidence,
albeit not always based on rigorous methodology, which attests to its
potential in addressing the seemingly intransigent problems of in-
equitable access to care, uneven distribution of quality of care, and
healthcare cost inflation. This is particularly notable in the case of
chronic disease management. Chronic diseases—such as heart dis-
ease, stroke, cancer, diabetes, pulmonary disease, and arthritis—‘‘are
among the most common, costly, and preventable of all health
problems in the U.S.’’24 Almost 50% of all adults have at least one
chronic illness. Approximately 70% of all deaths in the United States
are from chronic diseases, and an estimated 50% of all deaths are
from heart disease, cancer, and stroke. Increasing percentages (over
7%) of U.S. children and adolescents have a chronic disease condi-
tion. In terms of cost, approximately 75% of all healthcare expen-
ditures are spent on chronic illness. Thus, an intervention that (1)
promises to involve patients in their own care, (2) provides contin-
uousmonitoring by their healthcare providers, and (3) identifies early
symptoms and responds promptly to exacerbations in their illnesses
must be seriously considered and carefully assessed.
As with any other technology-based application, telemedicine has
costs and benefits. The costs include the necessary investment in
technology, human resources, and organizational development. Over
time, however, equipment and connectivity costs have declined sub-
stantially, whereas the capabilities have expanded at a phenomenal
rate. When properly, implemented telemedicine can enhance care co-
ordination across various providers, ensure continuity of care regard-
less of site, and enable on-site triage and prompt referral when needed.
Patients can receive appropriate and timely care from an appropriate
provider, whether locally or when determined to be suitable at tertiary-
care centers, as indicated by their condition. Patients in remote or
medically underserved locations can have ready access to clinical re-
sources and can be monitored in their home environment. In many
instances, telemedicine obviates the cost and time of travel to seek
medical services while providing diagnostic expertise normally avail-
able in tertiary-care centers. New models of accountable care organi-
zations and the patient-centered ‘‘medical home’’ also can incorporate
telemedicine services to improve their efficiency and effectiveness.
Within the current healthcare system, which is weighted heavily
toward acute care, the traditional model of care for those with chronic
health conditions can be aptly described as a ‘‘revolving door’’ ar-
rangement whereby patients are seen in a physician’s office, and future
appointments for return visits are scheduled at fixed ‘‘arbitrary time
intervals,’’ based, at least in part, on physician availability.25 Exacer-
bations in illness that occur in between appointments are handled
mostly by referral to the emergency room or urgent treatment center.
This arrangement is clinically and economically ineffective. In most
instances, the need for medical attention generally and among patients
with chronic illness in particular, cannot, a priori, be determined with
any accuracy. Hence, the formal and arbitrary scheduling of return visits
at fixed dates and times cannot be synchronized to match the timing
when patients need care, resulting in costly emergency room usage.
In 1997, it was observed that ‘‘available evidence suggests that
chronically ill patients receive limited assistance from their providers in
their efforts to maintain function and quality of life as they cope with
their illness.’’26 To address this problem, and while acknowledging
barriers in adopting it in its entirety, in 2002 Bodenheimer et al.27
proposed an ‘‘optimal’’ chronic care model for use as an universally
applicable guide to improve outcomes for individuals living with
chronic illness. Initially, implementation of the model required re-
organizing the care system, typically through a staff-model managed-
care plan. However, the same model was considered useful as a guide
for revisions at a number of integrated delivery systems that included,
at minimum, a hospital, office practice, and home care in the same
system. As posited, themodel predicted improvement in six interrelated
components (including self-management support, clinical information
systems, delivery system redesign, decision support, healthcare orga-
nization, and community resources) in which informed, activated pa-
tients interact with prepared, proactive care teams.
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In this model, the care system would be responsible for developing
patient registries and using them to ensure timely preventive and
maintenance services. Because the basic premise is to activate patients
in managing their own health, the model must ensure that they are
capable of self-care. The successful implementation of the model would
ultimately depend on the effective use of information technology.28
Telemonitoring
Telemonitoring or monitoring patients at a distance (also called
telehome care or home telecare—although telemonitoring now ex-
tends far beyond the home) is a component of a larger chronic care
model that includes disease management and care coordination, in
which patients assume a greater role in managing their health,
while having ready access to their providers who have up-to-date
information on various parameters of their health. It includes the
collection of clinical data from the patient and the transmission,
processing, and management of such data by a healthcare provider
through an interface system. As such, it represents an innovative
paradigm for the medical management of chronic illness, which
aims at providing ‘‘appropriate care at the appropriate time and
place in the most appropriate manner.’’25 The major pillars of tel-
emonitoring include patient-centered care, the medical home, and
shared decision making. When optimally implemented, patients are
electronically connected with their usual sources of medical care,
and teams of providers (nurses, physicians, and therapists) monitor
critical parameters (generally via sophisticated computer and al-
gorithm-based decision tools) affecting their health and well-being
and provide them with relevant advice, information, and follow-up
care. Under this system, patients would have:
. An electronic device that monitors and reports relevant data to
a provider team on a prespecified set of relevant vital signs and
other disease-specific parameters
. Relevant educational materials tailored to the individual patient
concerning medication management, symptom recognition,
especially when indicative of worsening conditions that require
action, as well as lifestyle preventive measures to improve their
health and well-being (such as proper diet, smoking cessation,
exercise, and moderate alcohol consumption)
. Ready access to their personal health records, including long-term
trends in their functional status, symptoms, and benchmarks
. Tools for participating in shared decision making together with
their providers and explicit guidance on the appropriate use of
service, such as when symptoms warrant a visit to the emer-
gency room or hospitalization, as well as when their conditions
do not warrant emergency care or hospitalization
. Ready access to medical advice when they have questions or
concerns
The preceding discussions were designed to provide a compre-
hensive context for the subsequent analysis of the evidence per-
taining to telemedicine’s role in chronic disease management. We
now turn to a review and analysis of the evidence.
The Review Process
This review is based on a systematic process for the selection of
relevant literature on the impact of telemedicine for the management
of three chronic diseases: CHF, stroke, and COPD. By design, the
review focuses on a limited set of representative chronic diseases
because of their current and increasing importance relative to their
prevalence, associated morbidity, mortality, and cost. Furthermore,
these three diseases are amenable to timely interventions and sec-
ondary prevention through telemonitoring. In each instance, we
provide a brief explanation of the disease entity as well as essential
information on its epidemiology and cost, as an appropriate context
for the search for evidence from the scientific literature. As men-
tioned earlier, a separate section addresses the issue of cost.
The review process entailed four steps: (1) a comprehensive search
for all publications using key terms such as ‘‘telemedicine,’’ ‘‘tele-
health,’’ ‘‘telemonitoring,’’ and each of the three chronic diseases to
identify the universe of publications available during 2000–early 2014;
(2) a paring down of this list to research articles only; (3) a review of the
abstracts of the research publications to determine their eligibility for
inclusion in the final list, using the two criteria of (a) robust research
design and (b) sample size of 150 or more; and (4) a review of complete
manuscripts of all publications in the final list. In a few instances, where
a special case could be made for their inclusion in the analysis, we
included studies with samples of fewer than 150 cases. In addition, we
reviewed the list of references in each of these publications to identify
articles that should be added to the final list. With the exception of two
studies from Germany, our search was limited to publications from all
countries where we could obtain an English version.
Because the studies did not use a standard methodological pro-
tocol, their respective findings and conclusions must be viewed from
the perspective of the specific methodological features that were
used, including research design, sample size, specific attributes of the
intervention itself, and the population studied. We tried to reduce
these variations by selecting only randomized clinical trials (RCTs) or
designs approximating an RCT and by limiting our analysis to studies
that had an adequate sample size for reliability and statistical power.
The methodologies used varied from one study to the next. They
differed in terms of the manner in which clinical and utilization data
were captured, transferred, processed, and stored (e.g., automated or
manual, machine captured or patient reported over time, with or
without trend displays, provider-only accessed or shared with the
patient), human health resources used (e.g., doctors, nurses, or
combinations of both), the content of the intervention (e.g., medi-
cation management, education, support), the protocols for frequency
(e.g., daily, weekly, monthly, etc.) and duration (e.g., from 1month to
5 years or more), and technology (e.g., telephone, video, automated
and manual devices).
There was also some variation in the outcomes measured. The
majority of studies focused on hospitalization and mortality as pri-
mary outcomes. Stroke studies, however, focused on event timing
from onset of symptoms to diagnostic tests to treatment, as will be
explained later. Hospitalization included all-cause and disease-
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specific hospital admissions, re-hospitalization, and length of hos-
pital stay. Mortality was typically treated as resulting from any cause.
Some studies focused on other outcomes, such as symptom severity,
physiological status, functional performance, quality of life, and
health knowledge. As far as we can determine, no study differentiated
between appropriate and inappropriate use of service (e.g., appro-
priate hospitalization or appropriate use of the emergency depart-
ment), and no studies addressed the cause of mortality.
CHF
CHF is a chronic, progressive condition in which the heart muscle
is unable to pump sufficient blood tomeet the body’s need for oxygen
and nutrients. Blood is responsible for transport of materials and
waste products throughout the body, carrying oxygen from and
carbon dioxide to the lungs, nutrients from the digestive system or
storage sites to tissues that require them, and waste products from
tissues to the liver for detoxification and to the kidneys for disposal.
When the heart muscle is weakened or stiffened, it compensates by
enlarging, developing more heart muscle or pumping faster. The
body also tries to compensate by narrowing blood vessels and di-
verting blood away from less important tissues to maintain the flow
to more vital organs.29
Cardiologists usually classify patients with heart failure according
to the severity of their symptoms and their eligibility for various levels
of treatment. However, there are several different classifications, and
serious concerns have been expressed about their validity. According
to current recommendations, a diagnosis of CHF requires typical
symptoms and signs together with evidence of abnormal cardiac
structure or function.30 In 1994, the New York Heart Association
(NYHA) developed an updated functional capacity/objective assess-
ment in four classes: no objective evidence of cardiovascular disease
(I) or objective evidence of minimal (II), moderate (III), or severe (IV)
cardiovascular disease, coupledwith limitations in physical activity.31
In 2005, the American College of Cardiology and the American
Heart Association published a combined functional/objective CHF
classification combining the NYHA functional categories with more
precise stages of heart failure. Patients in Stages A and B do not have
heart failure but have risk factors that predispose them to the de-
velopment of heart failure. Patients in Stage C comprise the majority
of patients with heart failure—those who have current or past
symptoms of heart failure associated with underlying structural heart
disease. Patients in Stage D have refractory heart failure and may be
eligible for specialized, advanced treatments.32
CHF EPIDEMIOLOGYa
In 2001, He et al.37 observed that ‘‘during the past several decades,
the incidence of and mortality from coronary heart disease have been
continuously declining. In contrast, the incidence of andmortality from
CHF have been increasing and have become important public health
and clinical problems.’’ Crude prevalence estimates show that in 2010,
6.6 million or 2.8% of U.S. adults older than 18 years of age had CHF.38
Based on data from the Framingham Health Study, the incidence of
CHF approached 10 per 1,000 of those over 65 years of age in 2002.39
The incidence of CHF varies considerably among racial/ethnic
groups, with a larger percentage of black males having CHF com-
pared with white males. Although the overall incidence is lower in
females than in males, the rate in black females tends to be higher
than that of while females. Annual incidence rates for heart failure
‘‘events’’ per 1,000 population for white men is approximately 15
cases for those 65–70 years of age, 32 cases for those 75–84 years of
age, and 65 cases for those older than 85 years of age. For black men
in the same age groups, the rates are approximately 17, 26, and 51
cases per 1,000, respectively. For white women in the same age
groups, the respective rates are 8, 20, and 46, whereas for black
women in the same age groups, the respective rates are 14, 26, and 44.
Although survival rates after CHF diagnosis have improved, overall
mortality remains high. It is estimated that approximately 50% of
people diagnosed with heart failure will die within 5 years.40
CHF COST
Heart failure is a growing public health problem in the United
States, with high morbidity and mortality rates and frequent hospital
admissions. In 2005, it was the primary reason for an estimated 12–
15 million office visits and 6.5 million hospital days. In the Medicare
population, CHF is the leading cause for hospitalization, accounting
for more than 1 million admissions per year.34 In 2010, the annual
cost of heart failure for the nation was estimated at $39 billion.41 This
includes the cost of medical services, medications, andmissed days of
work. The percentage of heart failure costs in relation to total costs
for cardiovascular disease has increased from approximately 24% to
37%. The largest percentage of costs is associated with hospital care
(60%), followed by nursing home care (13%), home healthcare and
medication (9% each), and physicians (7%).42 In 2009, the number of
hospitalizations per 10,000 population was 34.8 for persons 45–64
years of age and 197.5 for persons 65 years of age and older.42
CHF TELEMONITORING
CHF is not only a source of difficulty for patients and their families,
but also a serious public health burden for society. CHF patients suffer
from a poor quality of life coupled with short life expectancy. The high
mortality rate associated with CHF emphasizes the need to identify
modifiable risk factors and develop effective, efficient, timely, and cost-
efficient strategies for themanagement of CHF in the general population.
The essential element of telemonitoring is the reliance on information
technology for connecting patients and providers in a coordinated
system of care, described earlier. Telemonitoring figures prominently as
an efficient and effective model in the management of CHF.
EVIDENCE OF THE IMPACT OF TELEMONITORING
FOR PATIENTS WITH CHF
Our literature search for telemonitoring and CHF yielded an initial
total of 436 publications. Of these, only 19met the criteria for inclusion
aFor a more complete review of CHF epidemiology, see Mahmood and
Wang,33 Rathi and Deedwania,34 Zarrinkoub et al.,35 and Wong and Felker.36
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in the final analysis. In addition, we encountered 35 literature reviews
and 1 reviewof reviews.We did not include the literature reviews in our
analysis because our inclusion criteria excluded several studies that
were included in these reviews. Significant numbers of the studies in
our analysis were not limited to heart failure, and they included other
chronic diseases, although not consistently the same set.
This report is based on the findings from the select set of 19 studies
(shown in Table 1), dating from 2000 to 2013 in 10 countries (the
United States, the United Kingdom, Canada, Germany, France, Bel-
gium, The Netherlands, Italy, China, and Argentina). Forty-seven
percent of these studies were conducted in the United States.
As a prelude to the report of the findings from these studies, it is
important to point out again significant methodological issues that
may have a direct bearing on their findings. With four exceptions,
these studies used the RCT research design. Three of the four ex-
ceptions used a case control design in which cases in the intervention
group were matched prospectively or retrospectively to create a
control or comparison group. One large study in the United Kingdom
used ‘‘cluster randomization’’ in which whole groups of patients were
randomized on the basis of their usual sources of care. This method
does not assure the same level of randomization as individual case
randomization.
Sample sizes of the studies included here ranged from a low of 160
to a high of 17,025. The most critical problem in interpreting the
findings has to do with the variation along several different dimen-
sions in which the intervention was applied. From one study to an-
other, the intervention varied by technology, provider mix,
frequency, and duration as well as the illness severity in patient
populations. From a technology standpoint, they used a variety of
devices and various configurations of telephone, videoconferencing,
and automated devices. Staffing varied from nurses using telephones
to visiting nurses who conducted home visits to physicians. The
frequency of monitoring was typically daily but varied from twice
daily to every 3 weeks. The duration of observations varied from a
low of 3 months to 26 months, typically 12 months. Patient popu-
lations varied from young and middle-aged adults (18 years of age
and over) to older adults (65+ years of age) to the elderly (75 + years
of age). Some studies selected only patients classified as I or II (mildly
impaired) on the NYHA scale, whereas some selected only Classes III
and IV (moderately to seriously impaired). One study selected older
adults with multiple health issues. Moreover, some interventions
included educational content and/or medication management, and
some were limited to reporting of vital signs and responses to stan-
dard inquiries. Hence, generalization across studies is neither simple
nor straightforward.
We paid particular attention to findings pertaining to the effects of
telemonitoring on cost-intensive phases of medical care, including
emergency department visits, hospital admissions (for CHF only and
for all causes), and length of hospital stay. We also paid special
attention to health outcomes, typically measured in terms of mor-
tality. Where reported, satisfaction with service and quality of life are
also included in our discussion of findings. As it turned out, some
studies investigated the effects of telemonitoring on several chronic
diseases simultaneously, including CHF. When this occurred, we
reported their findings in one place only.
THE OBSERVED EFFECTS OF CHF TELEMONITORING
One of the earlier landmark studies was conducted in California at
Kaiser Permanente in the late 1990s (published in 2000) by Johnston
et al.43 It was based on a quasi-experimental design, and it evaluated
the effects of a videoconferencing system that ‘‘allowed nurses and
patients to interact in real-time.’’43 Both intervention and control
groups received home visits and telephone contact by nurses. The
study reported no differences in quality indicators (medication
compliance, knowledge of disease, and ability for self-care), patient
satisfaction, or use of service. However, the study reported significant
differences in direct cost between the intervention and control groups
($1,167 versus $1,830) as well as total cost ($1,948 versus $2,674).
(These figures are based on 1997 dollars and do not include the cost of
home health services.)
In 2002, another study in California (RCT, n = 358: intervention
group, n = 130; usual care group, n = 228) investigated the effects of a
nurse case management telephone intervention on resource use
among patients with CHF.44 Outcome measures included hospital
admissions and re-admissions, length of stay, emergency department
visits, and inpatient costs as well as patient satisfaction. The findings
from this study demonstrated that telephonic case management
provided by registered nurses using decision support software during
the early months following a heart failure hospitalization was asso-
ciated with significant cost savings (lower re-hospitalization rates
and use of other resources). As well, patients reported being satisfied
with the intervention, which proved useful in addressing predictors
associated with CHF hospitalization, such as poor adherence to
medication regimens and to dietary recommendations, and insuffi-
cient knowledge of symptoms of worsening illness. Heart failure
hospitalizations in the intervention group were significantly lower at
3 months (45.7%) and at 6months (47.8%). ‘‘There was no evidence of
cost shifting to the outpatient setting.’’44 In addition, both heart
failure–related hospital days and multiple re-admissions were sig-
nificantly lower in the intervention group at 6 months. The authors
concluded that telephonic case management in the early months
following CHF is more effective than standard pharmaceutical
therapy and other case management strategies.
Also in 2002 (published in 2003), investigators from several uni-
versities in the United States conducted amulticenter RCT (n = 280) to
evaluate the effects of daily weight monitoring and symptom re-
porting among ‘‘advanced’’ heart failure patients (NYHA Classes III
and IV) using the AlereNet system for a 6-month period.45 Although
the use of the AlereNet system was associated with a 56.2% reduction
in mortality, it did not increase hospitalization. The intervention
group experienced greater improvement in all quality of life mea-
sures, but the differences were not statistically significant. The un-
ique feature of this study was the strict adherence to ‘‘aggressive
guideline-driven heart failure care’’ by cardiologists with heart fail-
ure expertise. The authors explained that ‘‘heart failure hospitaliza-
tions may not be a failing of the patient’s own personal heart failure
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Table 1. Methodology and Findings Pertaining to Congestive Heart Failure
LITERATURE SOURCE METHODOLOGY FINDINGSa
HOSPITALIZATION
REFERENCE DATE COUNTRY DESIGN
SIZE
(N)
DURATION
(MONTHS) TECHNOLOGY ADMIT LOS ED MORTALITY QUALITY COMMENTS
Johnston
et al.43
2000 United
States
QE 212 17 T, VTC Y Y NM NM O Cost savings
Riegel et al.44 2002 United
States
RCT 358 6 T Y Y [ NM NM Inpatient HF costs 45.5%
lower at 6 months; nurse
used decision support
software.
Goldberg
et al.45
2003 United
States
RCT 280 6 T, HTM O O O Y [ NYHA Class III (75%), IV
(25%)
Cleland et al.46 2005 Germany,
United
Kingdom,
and The
Netherlands
RCT 426 8 T O O [ Y NM Usual care control group
mortality was 45%.
HTM O Y [ Y NM
Woodend
et al.47
2008 Canada RCT 249 3/6/12 T, VTC Y Y O NM NM 3 months of VTC with nurse
intervention
Darkins et al.48 2008 United
States
OS 17,025 53 T, VTC, HTM Y Y NM NM NM 25.9% utilization reduction
Dendale et al.49 2012 Belgium CRCT 160 6 HTM, T Y Y NM Y NM TM increases collaboration
Ferrante et al.50 2010 Argentina RCT 1,518 36 T Y NM NM O [ T coaching to improve diet,
weight, edema, and exercise
Weintraub
et al.51
2010 United
States
RCT 188 3 T, HTM Y Y O Y O NYHA Class II and III
patients
Chaudhry
et al.52
2010 United
States
RCT 1,653 6 T, HTM O O O O O Participation waned to 55%.
Giordano
et al.53
2011 Italy RCT 358 96 HTM, NC [ NM NM O [ Number patients on beta-
blockers decreased.
Koehler et al.54 2011 Germany RCT 710 26 HTM O O O O O NYHA Class II and III;
physician led
Landolina
et al.55
2012 Italy RCT 200 16 T, VTC, HTM O Y Y NM [ Fewer visits with TM and
increased efficiency
Chen et al.56 2010 China QE 550 6 T Y Y Y NM NM Overall lower total cost
Boyne et al.57 2012 The
Netherlands
RCT 382 12 T, HTM Y NM NM O NM Decrease in contact with
specialized nurses
Steventon
et al.58
2012 United
Kingdom
CRCT 3,230 12 T, HTM Y Y Y Y NM Better patient management
of CHF and clinical decisions
Baker et al.59 2011 United
States
QE 1,767 24 T, HTM NM NM NM Y NM Savings of 7.7–13.3%
Baker et al.60 2013 United
States
QE 1,767 24 HTM Y O O Y NM High impact on outcomes
Takahashi
et al.61
2012 United
States
RCT 205 12 VTC O O O [ O Older and sicker patients
aArrows indicate direction of change: increased ([) or decreased (Y).
CHF, congestive heart failure; CRCT, cluster randomized trial; ED, emergency department; HF, heart failure; HTM, home telemonitoring; LOS, length of stay; NM, not
measured; NYHA, New York Health Association; O, neutral outcome; OS, observational study; QE, quasi-experimental; RCT, randomized controlled trial; T, telephone; VTC,
video teleconference.
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care regimen.but rather a manifestation of their progressively ad-
vanced disease state.’’45 They also pointed out that restricting the
study to patients with advanced heart failure (NYHA Classes III and
IV) left unanswered the question of the effectiveness of the inter-
vention among those with moderate or mild heart failure.
Only three studies meeting our criteria for inclusion in this anal-
ysis were conducted between 2005 and 2010, whereas 13 were
conducted from 2010 to 2013. A Trans-European (United Kingdom,
Germany, and the Netherlands) RCT (n = 426) was conducted among
200 subjects at high risk for hospital re-admission and death.46 It
compared three modalities: (1) telemonitoring (twice daily with au-
tomated measurement), (2) nurse telephone support, and (3) usual
care for patients who were at high risk for hospitalization. The main
comparison of interest was between telemonitoring and nurse tele-
phone support. The study was conducted at 12 main and 4 satellite
hospitals in three countries, and it followed a uniform protocol for
data collection. After 8 months, the number of hospital admissions
was similar between the telemonitoring and telephone support
groups, whereas length of hospital stay was reduced by 6 days in the
telemonitoring group. Patients randomly assigned to the usual care
group had higher 1-year mortality (45%) compared with the nurse
telephone support (17%) and those receiving telemonitoring (29%).
In 2008, an RCT (n = 249) was conducted in Ontario, Canada in-
volving cardiac patients at high risk of hospital re-admission (NYHA
Class II or higher CHF; Canadian Cardiovascular Society Class I or II
angina).47 The intervention consisted of 3 months of videoconfer-
encing with a nurse, daily transmission of weight and blood pressure,
and periodic transmission of the 12-lead ECG. Within 48 hours of
discharge, a technician set up the monitoring equipment in patients’
homes and trained them on their use. Weekly videoconferences over
standard telephone lines were held with a nurse, during which time
the patient’s progress was assessed and self-care education was
provided. Data from electronic weight scales, blood pressure, and
ECG machines were transmitted via telephone lines to a central sta-
tion at the Heart Institute housing the patient’s electronic record.
After 3 months of observation, telemonitoring resulted in reductions
of 51% in hospital admissions and of 61% in length of stay but no
effect on re-admissions. After 1 year, hospital admission rates were
reduced by 45% in the intervention group, as well as a reduction of
21% in length of stay. Similar trends were observed in fewer emer-
gency department and outpatient cardiologist visits. Although the
rates in utilization of service declined over 1 year, the differences
between the intervention and control groups remained significant.
A 2008 Veteran’s Health Administration (VHA) case report48
provided a trend analysis for a cohort of 17,925 patients with chronic
conditions between July 2003 and December 2007. It was during this
period that the VHA introduced a national home telehealth program:
Care Coordination/Home Telehealth (CCHT). The purpose of the in-
tervention was to coordinate care for Veteran patients with chronic
conditions in order to avoid unnecessary admission to long-term
institutional care. The chronic conditions included CHF, diabetes
mellitus, hypertension, posttraumatic stress disorder, COPD, and
depression. The program was necessitated by changes in the demo-
graphic characteristics of the Veteran population and, more specifi-
cally, the need for the VHA to increase its non-institutional care
services by 100% over its 2007 level in providing care for an esti-
mated 110,000 non-institutional care patients in 2011. Now a routine
non-institutional care service, the CCHT involves the use of home
telehealth and disease management technologies as adjuncts to the
VHA’s existing health information technology infrastructure. The
CCHT provides a range of interventions, and decisions are made as to
which one is best suited for each individual patient. These include
videophones, messaging devices, biometric devices, digital cameras,
and telemonitoring devices. Twenty-five percent of the CCHT case-
load were composed of CHF patients only; another 33.3% had mul-
tiple conditions. Hospital admission data were collected for CCHT
patients during the year prior to enrollment in the CCHT program and
compared with data collected 6 months after enrollment. The overall
cohort reduction was 19.7%. However, the percentage decrease for
CHF patients was 25.9%. The major conclusion from the VHA as-
sessment was that ‘‘the CCHT is a practical and cost-effective means
of caring for populations of patients with chronic disease that is
acceptable to both patients and clinicians.’’48
Acknowledging the need for an extensive reorganization of the
healthcare system in Belgium to prevent unnecessary re-hospitaliza-
tion, an RCT (n=160) was conducted among male CHF patients dis-
charged from seven hospitals to assess the effects of a telemonitoring
intervention on re-hospitalization and mortality rates among patients
with severe heart failure. The study was conducted in 2010 and pub-
lished in 2012.49 The intervention group was assigned to tele-
monitoring-facilitated collaboration between their general practitioner
(GP) and heart failure clinics. Upon discharge from the hospital, pa-
tients in both intervention and control groups received a standard
education course on heart failure and were instructed on how to use an
electronic body weight scale, a blood pressure monitoring device, and a
cell phone. In addition, the intervention group was given automated
telemonitoring devices that reported body weight, blood pressure, and
heart rate each morning at a fixed time. The scale and sphygmoma-
nometer were connected to a dedicated cell phone,which automatically
forwarded the results to a central computer programmed to alert both
the primary care physician and the heart failure clinic via automatic
e-mail alerts. This system limited calls that fell outside prescribed pa-
rameters. The total number of days lost to hospitalization, death, or
dialysis among CHF patients was significantly lower for the interven-
tion group compared with the usual care group (13 days versus 30 days,
p=0.02). Similarly, during the study period, hospital admission rates
for heart failure per patient were significantly lower (0.24 versus 0.42)
for the telemonitoring cohort.
In contrast to studies using smaller samples, shorter follow-up,
and sicker patients, a large sample study (n = 1,518 recruited from
51 participating health centers), with a longer duration (1½- and
3-year follow-up) and generally stable patients, was conducted in
Argentina.50 It was aimed at assessing the effects of a telephone
intervention on improving patient education and compliance and
subsequently on hospitalization and death. The study compared a
centralized regular telephone intervention with usual care for
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outpatients with stable, chronic heart failure. Patients in the inter-
vention group received an explanatory booklet and were followed up
via telephone by specialized nurses. The intervention objectives were
to improve dietary and treatment compliance, to promote exercise, to
regularlymonitor symptoms, weight, and edema, and to promote early
visits if signs of deterioration were detected. All patients were called
every 14 days (a total of four times) after randomization. Subsequent
call frequency was adjusted on the basis of case severity and com-
pliance. In other words, thosewith severe conditions andwhowere less
compliant were contacted more frequently. Under supervision of a
cardiologist, nurses were allowed to make short-term changes in di-
uretics and suggest unscheduled visits to the cardiologist. Control
group subjects continued treatment with their cardiologists in the
usual manner. A significant difference between the two groups was
observed with regard to hospitalization: 16.7% of patients in the in-
tervention group and 22.3% in the control group had an admission for
heart failure, but there was no significant effect on mortality. One year
later, 22.9% of the intervention group and 29% of the control group
had been admitted to the hospital. Three years later, 28.9% of the
intervention group and 35.1% of the control group had been admitted.
Moreover, patients who scored high on three compliance indicators
(diet, weight, and medication) had lower risk events. The study authors
observed that a ‘‘simple, nurse-based telephone intervention was as-
sociated with a clear clinical benefit for patients with CHF one and
three years after the intervention stopped.’’50
A 2009 (published in 2010) U.S.-based multicenter RCT (n = 188)
investigated the effects of automated home monitoring and tele-
phonic disease management.51 Patients in the intervention group
received an automated home monitoring system, whereas those in
the control group received ‘‘Specialized Primary and Networked Care
in Heart Failure.’’ The end point was hospitalization within 90 days.
Patients in the intervention group had fewer hospitalizations com-
pared with their counterparts.
In 2010, a U.S. large multi-institution RCT (n = 1,653) investigated
the effects of telemonitoring using the Pharos Tel-Assurance system
for patients with heart failure on hospital re-admission for any reason
or death within 6 months of enrollment.52 Secondary outcomes in-
cluded hospitalization for heart failure, length of hospital stay, and
number of hospitalizations in 6 months. All patients (in both inter-
vention and control groups) received educational materials and a
weight scale. Also, all patients were told to contact their clinicians
directly with any urgent concern. Hence, this was a comparison be-
tween two robust treatments, and the data for the intervention group
were self-reported by patients using an interactive voice recognition
system. The participation rate (adherence to the intervention) started
at 90.2% in the first week but dropped to 55.1% by week 26. By the
final week of the 6-month study, ‘‘only 55% of the patients were still
using the system at least three times a week.’’52 It is not surprising that
the authors concluded that their ‘‘telemonitoring strategy failed to
provide a benefit over usual care’’ with respect to hospitalization and
mortality. They did not report any cost data.
Another long-duration (8-year) study (n = 358) was conducted in
Italy.53 It investigated the effects of weekly nurse telephone tele-
monitoring and physician follow-up only when needed. Data were
gathered prospectively over a period of 8 years following the inter-
vention. The findings suggest improvements in clinical, functional,
and quality of life measures as well as lower hospital re-admissions
for cardiovascular reasons.
A single-site RCT (n=710) involving medium-severity CHF patients
was conducted in Germany in 2011.54 The telemedical management
was led by physicians, and the median follow-up was 26 months
(minimum, 12 months). The intervention consisted of portable devices
for ECG, blood pressure, and body weight measurement, which were
connected to a personal digital assistant with cell phone transmission.
The study population consisted of adults 18 years of age or older with
NYHA Class II or III (Classes I and IV were excluded). Among patients
assigned to the intervention group, 81% provided at least 70% of their
daily data transfers. Hence, about 20% did not participate, and of those
who participated, 30% did not comply with daily transmission of
monitoring data. The results were mostly neutral—showing no statis-
tically significant differences in mortality or other event-based out-
comes. Overall results suggest that physician-led telemedical
management ‘‘was not associated with a reduction in all-cause mor-
tality.’’54 However, fewer hospitalizations were observed in the inter-
vention group compared with the control group (14.7% versus 16.5%).
In 2008–2009 (published in 2012), Italian researchers conducted a
multicenter RCT (n = 200) to investigate the effects of remote moni-
toring on emergency room visits for CHF patients with implantable
cardioverter defibrillators (ICDs).55 They compared remote monitoring
with standard patient management consisting of scheduled visits and
patient response to audible ICD alerts. The primary end point was the
rate of emergency department or urgent in-office visits for heart
failure, arrhythmias, or ICD-related events. The intervention consisted
of implanting heart failure patients with a wireless-transmission-
enabled ICD/cardiac resynchronization therapy endowed with specific
diagnostic features (remote arm/home monitor), thereby increasing
efficiency compared with the standard management protocol (stan-
dard arm). A significant difference in emergency department/urgent
in-office visits between the groups was documented. Of a total of 192
visits, 75 were made in the ‘‘remote arm’’ group and 117 in the
‘‘standard arm’’ group. Compared with standard management, remote
monitoringwas significantly associatedwith a reduction of emergency
department/urgent in-office visits for episodes of heart failure wors-
ening. The authors noted that in addition to reductions in emergency
room visits, there was an overall increase in the efficient use of
healthcare providers and improved quality of care. But, quality of care
was not expressed in quantitative terms.
Similar findings were reported from a 2010 study in China in
which 550 heart failure patients were randomized to an intervention
consisting of nursing telephone consultations versus a control group
receiving the usual standard of care.56 After 6 months, the inter-
vention group had a significantly lower all-cause admission rate, a
shorter all-case hospital stay (8 days fewer per patient), and overall
lower total cost.
A multicenter RCT (n = 382) was conducted in The Netherlands in
2012 to ascertain the effects of telemonitoring on heart failure
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hospitalization over a 1-year follow-up period.57 The intervention
group received a liquid crystal display device with four keys con-
nected to a landline phone, but there was no automatic transfer of
vital signs. Information on heart rate and blood pressure for both
intervention and control groups was collected during regular clinic
visits. The intervention group had daily preset dialogues regarding
symptoms, knowledge, and behavior. Although telemonitoring had
no impact on initial CHF hospitalization, it was found to reduce heart
failure re-admissions and to decrease contact with specialized nurses.
A large study (n= 3,230 from 179 sites in three areas in England)
investigated the impact of remote exchange of data via a range of
devices and monitoring systems for patients with CHF, COPD, and
diabetes.58 This was a ‘‘cluster randomized trial,’’ which means ran-
domization was done by clusters (or clinics) rather than individuals,
and it used a relatively costly intervention for the electronic exchange
of information between patients and providers. During the 12-month
clinical trial period, patients in the intervention group were signifi-
cantly less likely to be hospitalized (odds ratio of 0.82) and signifi-
cantly less likely to die, compared with patients in the control clusters.
Although the investigators recognized the potential for selection bias
because of group rather than individual randomization, they tried to
match groups by practice size, disease prevalence, and other char-
acteristics. The study concluded that the telemedicine intervention
could serve several purposes: namely, to help patients manage
chronic disease better, to change patients’ perceptions as to when they
need to seek additional support, and to assist professionals’ decisions
regarding when to refer or admit patients.
The findings from a large study (n = 1,767) of Medicare benefi-
ciaries reported significant savings among patients who used the
Health Buddy program in 2011.59 The intervention accounted for
7.7–13.3% savings per person per quarter as well as ‘‘noticeable
change in health outcomes.’’59 The mortality rate in the second year
of observation was 2.5% lower in the intervention group. It is im-
portant to note that these findings were based on a retrospective
matched cohort design that relied heavily on ‘‘intent to treat,’’ neces-
sitated by the low level of participation in the intervention. Only 37%
of those assigned to the intervention group actually agreed to par-
ticipate. A later analysis of data on the same population (n= 1,767)
focused on mortality, hospital admissions, and emergency department
visits.60 After 2 years, patients using the Health Buddy program had a
15% reduction in mortality risk and an 18% reduction in quarterly
hospital admissions. The strongest effects were observed on admis-
sions among COPD patients and on mortality among CHF patients and
among those labeled as ‘‘engaged.’’
A U.S. RCT (n=205) (published in 2012) reported an increase in
mortality and no impact on use of service among the intervention
group.61 The intervention group received the IntelHealth Guide, a high-
end device with videoconferencing and peripheral attachments. Pa-
tients performed daily sessions to assess symptoms and biometric
measurements, which were relayed asynchronously to a nursing sta-
tion. A registered nurse monitored data and communicated with pa-
tients (approximately 100 patients, which corresponds to the total
number of patients in the intervention group) by phone or video when
alerts were triggered. The usual care group had access to primary and
specialty care, telephonic nursing care, urgent care, and emergency
department services. The decision triage was made by the nurse with
decision support assistance from an electronic medical record. The
results showed no difference between the two groups in terms of hos-
pitalization or emergency department visits, but mortality (causes
unknown) was higher in the telemonitoring group (14.7% versus 3.9%).
Because this was the only study in our review that reported the
intervention group experiencing higher mortality than the control
group, a closer examination of the methodology of this study may
provide a better understanding of the results. The study population
consisted of elderly patients with multiple health issues, putting them
in the top 10% on the Elder Risk Assessment Index—an electronic
database used to assess risk for hospitalization and comorbidities
(stroke, dementia, heart disease, diabetes, and COPD). The average
age of study participants was 80.3 years. Also, baseline comparison
between the intervention and control groups revealed slightly lower
mental health scores for the intervention group. During the 12-
month study, 26 patients (25.5%) of the intervention group dropped
out, which represented 15 deaths and 11 withdrawals. This compares
with only 12 who dropped out from the usual care group (11.7%),
representing four deaths and eight withdrawals. The analysis was
made on the basis of the entire original groups in the study using the
intent-to-treat method. In other words, utilization and mortality data
were imputed for those who died or dropped out. The authors con-
cluded that mortality experience of patients in the intervention group
was consistent with ‘‘previous experience.’’ No information was
provided on the timing or the causes of death in the two groups, and
there was no analysis of potential bias that may have been introduced
as a result of nonparticipation.
An invited commentary by Wilson62 sheds further light on the
environment where the study was conducted, indicating that the
study groupwas composed of ‘‘highly educated and affluent residents
of Olmsted County, Minnesota, that may not benefit from telehealth
because such patients are highly activated and engaged in their own
health at baseline.’’ He cautioned against either a dismissal or a
negative indictment of telemedicine as a potentially useful technol-
ogy and pointed out that ‘‘the effectiveness of telehealth programs
would be mediated by an array of patient, physician, and larger
health system factors, as well as by factors related to the details of the
implementation of the telehealth program.’’62 It is also important to
consider the metrics for evaluation. The focus on hospitalization and
emergency visits would ignore other outcomes, such as healthcare
spending, outpatient visits, and quality of life.
Stroke (Cerebrovascular Disease)b
Stroke is the fourth leading cause of death in the United States
and is the leading cause of brain damage. Often referred to as
bInformation on stroke was compiled several sources, including the Ameri-
can Heart Association/American Stroke Association,63 the National Institute
of Neurological Disorders and Stroke,64 and Go et al.65
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cerebrovascular accident, a stroke occurs when the blood supply to
part of the brain is suddenly occluded or when a blood vessel in the
brain bursts (or ruptures), causing damage to the brain. When part
of the brain cannot get the necessary blood and oxygen it needs, the
affected brain cells die. Stroke can be caused by a clot obstructing
the flow of blood to the brain (ischemic stroke), bleeding within the
brain (spontaneous intracerebral hemorrhage), or rupture of a
weakened blood vessel around the brain (subarachnoid hemor-
rhage). A transient ischemic attack (TIA), or ‘‘mini stroke,’’ is a
temporary neurologic deficit that resolves leaving no residual
damage.
Ischemic stroke accounts for about 83–87% of all cases, whereas
hemorrhagic stroke accounts for about 13–17% of stroke cases. The
majority of the latter are intracerebral hemorrhage, a devastating
condition frequently resulting in a 30-day mortality of up to 50%.
Smaller numbers of hemorrhagic strokes are caused by subarachnoid
hemorrhage. These typically result from rupture of intracranial an-
eurysm or arteriovenous malformations, head trauma, or clotting
disorders (include use of anticoagulant medications). It is estimated
that between 1.5% to 5% of the general population have or will
develop a cerebral aneurysm. About 3–5 million people in the United
States have cerebral aneurysms, but most do not have any symptoms.
Between 0.5% and 3% of people with a brain aneurysm may suffer
from bleeding. Brain aneurysms differ considerably in size, shape,
and location, but they are especially likely to be found in the anterior
or posterior communicating arteries or the internal carotids.
A TIA can last minutes to hours. It occurs when the blood supply to
part of the brain is briefly interrupted, and it is a risk factor for sub-
sequent stroke. A TIA is generally thought to be caused by a clot. The
primary difference between a stroke and TIA is that the blockage in TIA
is temporary, although in some cases there may be some injury to brain
tissue. In the earliest stages of ischemic neurologic deficit, there is no
way to tell if the individual is experiencing a TIA or a major stroke.
A strokemimic is a condition that can present similarly to ischemic
stroke and may give a false-positive diagnosis of stroke. When it
occurs, a patient initially diagnosed with stroke ultimately gets an
alternate diagnosis, including seizure, conversion disorder, or en-
cephalopathy. Hence, it is important to understand the role of tele-
stroke in differentiating mimics from actual stroke.
Stroke can produce a wide range of neurological deficits that can
significantly alter quality of life. A common disability that results
from stroke is paralysis on one side of the body, which can be
complete (hemiplegia) or partial (hemiparesis). Stroke may also cause
problems with thinking, awareness, attention, learning, judgment,
sensation, and memory. Stroke survivors often have problems un-
derstanding or using speech. A stroke can lead to emotional problems
such as difficulty controlling one’s emotions or inappropriate ex-
pressions of emotions. Depression is common. Stroke survivors may
also experience numbness or strange sensations.
Fewer people are dying of stroke today. The age-adjusted stroke
mortality rate has decreased 70% since 1950 and 33% since 1996.
However, as the population ages, further advances are needed to keep
pace.66 It remains a leading cause of disability in the United States.67
STROKE EPIDEMIOLOGYc
Stroke kills approximately 130,000 Americans each year, ac-
counting for 1 out of every 19 deaths.d On average, one American dies
from stroke every 4 minutes. Between 2007 and 2010, an estimated
6.8 million American ‡ 20 years of age have had a stroke (extrapo-
lated to 2010 fromNational Health andNutrition Examination Survey
2007–2010 data) and were living with its impact every day. During
this period the overall stroke prevalence was an estimated 2.8%.65
Considered a precursor to symptomatic stroke and progressive
brain damage, silent cerebral infarction is a brain lesion presumably
resulting from vascular occlusion found incidentally by magnetic
resonance imaging.69 The prevalence of silent cerebral infarction is
estimated to range from 6% to 28% of the population, with higher
prevalence associated with increasing age and varying with ethnic-
ity, sex, and risk factor profile.70
Based on the latest available data, on average, every 40 seconds,
someone in the United States has a stroke.65 In a national cohort
study, the prevalence of at least one stroke-related symptom among
those free of a prior diagnosis of stroke or TIA and older than 45
years of age was approximately 18%.71 Projections indicate that an
additional 3.4 million people ‡ 18 years of age will have had a
stroke by 2030, a 20.5% increase in prevalence from 2012. The
highest projected increase (29%) is expected to occur among His-
panic men.72
The data on stroke prevalence are unclear. However, there is
general agreement that women have a higher prevalence rate at all
ages, whereas men have a higher death rate due to stroke.65,73
In total, 27,744 participants in a national ‘‘Reasons for Geo-
graphic and Racial Differences in Stroke (REGARDS) Study’’ were
followed up for 4.4 years between 2003 and 2010. In this cohort, the
overall age- and sex-adjusted black/white incidence ratio was 1.51,
but for those 45–54 years of age it was 4.02. However, the black/
white incidence ratio for those ‡ 85 years of age declined to 0.86.71
In a population-based stroke surveillance study (2000–2010),74
significant ethnic disparities in stroke rates for people in the 45–
59-year-old and 60–74-year-old age groups persisted (but not in
for people > 75 years of age) despite significant declines in ische-
mic stroke rates between Mexican Americans and non-Hispanic
whites ‡ 60 years of age.
cAlthough based on findings reported in the current literature, the stroke
prevalence and incidence estimates presented here are based on a consid-
erable number of diverse study populations, in terms of sample size, geo-
graphic setting, and time period. The reader should, therefore, exercise
caution in extending and/or assigning validity/accuracy to the estimates
presented vis-a`-vis current populations and subpopulations. For a more
comprehensive review, the reader is referred to Go et al.65
dIn fact, treatment of stroke has risen to a cross-national goal as stated in the
World Health Organization’s Helsingborg Declaration of 2006. One of the
goals for 2015 pertained to the organization of stroke services and specifi-
cally stated that ‘‘a system be established to incorporate new achievements
into stroke care.’’68
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STROKE RISK FACTORS
More than 20 ‘‘leading’’ risk factors have been associated with stroke,
including controllable medical risk factors and lifestyle risk factors, as
well as uncontrollable risk factors.75 Medical risk factors include atrial
fibrillation, diabetes, high blood pressure, and chronic kidney disease.
Lifestyle factors include smoking, physical inactivity, and obesity.
Moreover, a documented parental ischemic stroke by the age of 65 years
was associated with a threefold increase in ischemic stroke risk among
their offspring, even after adjusting for other known stroke risk factors.
STROKE COSTS
Stroke is a major cause of death and long-term disability with
potentially enormous emotional and socioeconomic results for pa-
tients, their families, and health services. In spite of the high cost
burden, only limited numbers of recent studies have focused on
stroke-related costs in the United States.76 These costs have been es-
timated at about $36.5 billion annually, including the cost of
healthcare services, medications, and lost productivity.65 Lifetime
costs per stroke patient were estimated at between $59,800 and
$230,000.77 Brown et al.78 at the University of Michigan (published in
2006) projected U.S. costs of ischemic stroke from 2005 to 2050 (in
2005 dollars) to be approximately $2.2 trillion: $1.52 trillion for non-
Hispanic whites, $313 billion for Hispanics, and $379 billion for Af-
rican Americans.79 Assuming a 3% yearly inflation from 2008, total
direct and indirect costs of stroke in the United States was projected to
be $108 billion in 2025.79 Based on the National Inpatient Sample,
hospitalization costs for ischemic stroke patients in the United States
treated with intravenous thrombolysis were assessed from 2001 to
2008.80 Median hospital costs in 2008 dollars were $14,102 (inter-
quartile range, $9,987–20,819) for patients with good outcome,
$18,856 (interquartile range, $13,145–30,423) for patients with se-
vere disability, and $19,129 (interquartile range, $11,966–30,781) for
patients with in-hospital mortality. Average 2008Medicare payments
were $10,098 for intravenous thrombolysis without complication and
$13,835 for intravenous thrombolysis with major complication.
TELESTROKE
The term ‘‘telestroke’’ was introduced in the published literature in
199981 as an ICT-based solution to overcome the shortage of stroke
expertise in many areas of the country. It came after the introduction
of thrombolytic treatment with intravenous tissue plasminogen ac-
tivator (tPA) (approved by the Food and Drug Administration in
1996) and reflected the urgent need to increase its appropriate ad-
ministration during the ‘‘golden hour,’’ initially set at 3 hours after
the onset of symptoms and now extended to 4.5 hours. The timely
administration of tPA increases the probability of a favorable out-
come substantially, with an odds ratio of 2.55 in comparison with no
treatment. However, this requires strict adherence to explicit proto-
cols and close supervision by a stroke specialist. Because tPA dis-
solves the clot causing the stroke, it can also cause bleeding into the
brain or other serious bleeding that may lead to death. Indeed, if tPA
is administered in cases of hemorrhagic stroke or stroke mimics, it
can be fatal or cause severe disability.
Stroke presents a very different kind of health problem when
compared with heart failure. The onset of stroke is sudden and often
unexpected. Its prompt and accurate diagnosis and treatment can
produce optimal outcomes, both short term and long term. Hence, the
critical variables in the intervention are based on timing: from onset
of symptoms to proper diagnosis, to initiation of appropriate treat-
ment, to transfer of patients, as indicated in each case. A crucial
initial step is a computed tomography (CT) scan of the brain to de-
termine whether the stroke is ischemic (about 87% of cases) or
hemorrhagic (about 13% overall: 10% intracerebral and 3% sub-
arachnoid [that is, between the pia and arachnoid membranes that
surround the central nervous system]). The clinical protocols for these
conditions are well established even though their implementation
may not be uniform. Ischemic stroke may be treated by tPA, while
balancing the risks and the benefits as they pertain to the charac-
teristics of individual patients. Hemorrhagic stroke may require more
complex interventions, including surgery.
Some stroke patients may be successfully treated in their local
community hospital under remote supervision by a stroke specialist
without being transferred to a stroke center. Some may have intrave-
nous tPA treatment started on-site before being transferred (also referred
to as ‘‘drip and ship’’), and some may require prompt transfer to a stroke
center for extensive interventions. Telestroke is often practiced within
established hub-and-spoke networks. More recently, with the avail-
ability of more bandwidth and security arrangements (such as operating
within protected virtual private networks), the Internet has been used as
a more inclusive and much broader network for stroke treatment.
Because of the differences between heart failure and stroke, the focus
and methodology for assessing the effects of telestroke vary consid-
erably from those of telemonitoring for heart failure. Whereas tele-
monitoring of heart failure typically provides long-term support and
ongoing service to help patientsmaintain an optimal level of health and
functioning for the remainder of their lives, including patient-specific
medication regimen and healthy lifestyle, telestroke systems typically
consist of prompt interventions aimed at optimal treatment. Telestroke
is based on an explicit evidence-based protocol for the timely admin-
istration of thrombolytic treatment, when indicated, and the transfer of
patients requiring more intensive interventions.
Telestroke systems typically consist of networks wherein com-
munity and rural hospitals are electronically linked with medical
centers containing stroke expertise. In some instances, tPA is ad-
ministered on-site with supervision by the remote stroke specialist.
When patients present complex conditions that require critical care
or surgical or arterial interventions, they are transferred to tertiary-
care centers. If patients experience a worsening of symptoms after
tPA, a CT scan of the brain and cessation of the medication are
indicated, and the patient would be transferred to a stroke center.
THE SEARCH FOR EVIDENCE
Using the terms telemedicine/telehealth and stroke, our initial lit-
erature search yielded 422 publications. The four-step review process
described earlier in the section on CHF resulted in a final list of 21
publications for full review (Table 2). The selection criteria for
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Table 2. Methodology and Findings Pertaining to Stroke
LITERATURE SOURCE METHODOLOGY FINDINGS
REFERENCE DATE COUNTRY DESIGN
SIZE
(N)
DURATION
(MONTHS)
TELEMEDICINE
TECHNOLOGY
FEASIBILITY
AND
RELIABILITY
EVENT
TIMINGa
HEALTH
OUTCOMESb COMMENTS
Khan et al.82 2010 Canada PCC 210 24 T Yes [ O No difference between T and
VTC
VTC [
Gonzalez et al.83 2011 United States PCC 960 NR CVP Yes Y O 38 seconds longer than
bedside
Demaerschalk
et al.84
2012 United States PCC 100 NR Network Yes NM O NIHSS: 8 high, 6 moderate, 1
poor agreement (ataxia)
Allibert et al.85 2012 France RCC 161 72 VTC Yes NM O LOS shorter
Pervez et al.86 2010 United States RR 296 3/6 T, VTC Yes [ O ‘‘Drip and ship’’ is safe/
effective; spoke patients less
severe
Spokoyny et al.87 2014 United States RCT 261 NR T, VTC Yes NM [ Telestroke evaluation of head
CT scans for acute tPA
assessments is reliable.
Demaerschalk
et al.88
2012 United States 2 RCTs 276 3 T, VTC VTC better [ VTC > T VTC higher sensitivity than
phone
Handschu et al.89 2008 Germany PCC 151 12 T, VTC Yes VTCY; T[ [ Exam times (VTC, 49.8
minutes/T, 27.2 minutes)
Puetz et al.90 2012 Germany PCC 536 NR Network Yes NM [ Stroke neurologists can
reliably interpret CT scans.
Mu¨ller et al.91 2006 Germany PCC/RCC 299 24 VTC Yes NM [ All quality indicators
improved; LOS lower
Audebert et al.92 2009 Germany NR 267 3 VTC Yes [ O Acceptance high and stable
Pedragosa et al.93 2009 Spain RCC/PCC 201 12 VTC Yes [ [ Telemedicine allowed 38%
(from 17%) neurologist
evaluation
Nagao et al.94 2012 Australia RR 275 12 VTC Yes [ O Telestroke faster, safe,
reliable
Sairanen et al.95 2011 Finland PCC 985 24 VTC Yes [ O On-site versus telestroke
similar results
Rudd et al.96 2014 United
Kingdom
RCC 2,922 36 T Yes TY O In-person 65 minutes, T 73
minutes
Bruno et al.97 2013 United States RR 889 20 VTC Yes [ [ Registration delay (median
39 minutes)
Pedragosa et al.98 2012 Spain PCC 119 24 VTC [ Endovascular
treatment
[ [ Saved time in endovascular
treatment
Walter et al.99 2012 Germany RCT 100 Stopped at 100
patients
MSU MSU feasible/
reliable
[ O Timing improved
Audebert et al.100 2009 United
Kingdom
PCC 3,060 12/24 VTC Yes [ [ Long-term benefit for acute
stroke patients
Theiss et al.101 2013 Germany LS 1,152 48 VTC Yes [ [ Increased teleconsultations
and 45% increase in protocol
conformity
Switzer et al.102 2013 United States PCC 1,112 60 VTC Yes [ [ Spoke hospitals more
effectively used
aArrows indicate direction of change: faster or increased use ([) or slower or decreased use (Y).
bArrows indicate direction of change: improved ([) or declined (Y).
CT, computed tomography; CVP, cellular videophone; LS, longitudinal study; MSU, mobile stroke unit with computed tomography scanner; NIHSS, National Institutes of
Health Stroke Scale; NM, not measured; NR, nonrandomized; O, neutral outcome; PCC, prospective case control; RCC, retrospective case control; RCT, randomized
controlled trial; RR, retrospective review; T, telephone; t-PA, tissue plasminogen activator; VTC, video teleconference.
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telestroke studies had to be adapted because the RCT requirement could
not be met in most cases. Stroke studies do not readily lend themselves
to case randomization and prospective observation or blinding for
clinical and ethical reasons. Because the relative efficacy and safety of
the clinical protocols are well established, denying appropriate treat-
ment for patients in the control group would not be justified.
There are, however, other methodological options that enable reli-
able and valid assessment of the effects of telestroke under these con-
ditions. These methodologies include variations of the case control
study design, where cases in the intervention group are matched either
prospectively or retrospectively to create the control group. Such quasi-
experimental designs have the unique advantage of ready access to
large samples, they are substantially less costly than RCTs, and they do
not violate any potential ethical rules in informed consent. The typical
statistical measure of effect in the case control design is usually given as
an odds ratio (i.e., the effect of telestroke, given the alternative).
The telestroke evidence presented here covers the period from
2005 through the spring of 2014. Unless otherwise noted, our anal-
ysis of the findings is limited to studies during this period with a
minimum sample size of 150 and a robust research design (typically
case–control quasi-experimental design).
The findings can be grouped into three sets: (1) feasibility and
reliability of telestroke, (2) intermediate outcomes: event timing in
the care process (time lapse between onset of symptoms, diagnostic
tests and treatment), and (3) health outcomes and cost. As mentioned
earlier, the findings from studies that incorporated more than one
chronic condition are discussed only once.
Feasibility and reliability. Initially, we report the findings from six
studies (three from the United States and one each from Canada,
France, and Germany) that investigated the feasibility and/or reli-
ability of telestroke. In 2010, a study reported on a 2-year experience
with 210 patients with acute stroke who were referred to the tele-
stroke program serving remote hospitals in Alberta, Canada.82 Tele-
phone and video were both used in connecting the remote sites to the
University of Alberta Hospital. Over a 2-year period, 77% of patients
in the video group received thrombolysis versus 45% in the telephone
group. Over 21% of patients were treated with tPA at their local
hospital. The authors concluded that telestroke is not only feasible,
but it can also significantly reduce the need to transfer patients.
Furthermore, the study suggests the value of visual information.
A 2011 study tested the feasibility and reliability of using a vid-
eophone to assess compliance with the National Institutes of Health
Stroke Scale (NIHSS) in patients with acute stroke before they were
admitted to the hospital.83 A cellular videophone with two-way audio
and one-way video was used to connect patients from the originating
site. In total, 480 paired comparisons by 40 physicians were gener-
ated to assess the feasibility and reliability of the videophone vis-
a`-vis bedside stroke management. Performing the NIHSS over
videophone took 38 seconds longer than the bedside examination,
but it was equally reliable.
A somewhat similar study in 2012 compared the reliability of a
video smartphone (i.e., Apple [Cupertino, CA] iPhone 4) with bedside
observation for assessing NIHSS in acute stroke patients and reported
similar results.84 One hundred consecutive patients 30–96 years of age
presenting at theMayo Clinic with a suspected strokewere observed at
the bedside and via video (which captured verbal responses, actions,
and body expressions). Of these, 46.8% had a final diagnosis of is-
chemic stroke, 8.7% of transient ischemic attack, 7.5% of hemorrhagic
stroke, and 36.1% of stroke mimics; 0.96% of the diagnoses were
uncertain. Among ischemic alert patients, 14.1% received tPA, 3.5%
received tPA plus intra-arterial treatments, and 4.0% received intra-
arterial treatment only. The authors concluded that the iPhone was ‘‘a
very reliable tool for stroke telemedicine.’’84 Moreover, physicians
were highly satisfied with the iPhone in this context.
In 2012, a French study compared the efficacy and safety of
thrombolytic treatment of ischemic stroke at a distant hospital via
telemedicine.85 A retrospective analysis of 161 patients over a 6-year
period compared the experience of a university hospital versus a
remote hospital via telemedicine. No significant differences were
observed between the two settings.
In another study, data were abstracted from patient records to
ascertain the feasibility and safety of telestroke services provided in a
regional network. The complications and outcomes of 296 patients
with acute ischemic stroke were compared with those receiving tPA
treatment using ‘‘drip and ship’’ treatment and those treated at the
regional stroke center.86 Patients at the ‘‘spoke hospital’’ were
younger with fewer severe symptoms. The outcomes of the two
groups were similar. Among survivors, length of stay among spoke
hospital patients was shorter. However, these differences may be
explained by the selectivity of the two groups.
A somewhat different methodology was used in a pooled analysis
of data from Arizona and California.87 The data were derived from
prospective, randomized, outcome-blinded studies comparing tele-
medicine/teleradiology with telephone-only consultations. Inter-
observer reliability was ascertained between the hub vascular
neurologist (telemedicine arm) and the spoke radiologist (telephone
arm) regarding contraindications for tPA, hemorrhage, tumor, hy-
perdense artery, acute stroke, prior stroke, and ischemic changes.
There was substantial agreement (over 94% for all measures) between
vascular neurologists and radiologists at spoke sites. This study
demonstrated that telestroke evaluation of head CT scans for acute
tPA assessments is reliable. Furthermore, pooled analysis from the
same trials and based on a total of 276 patients reported that correct
thrombolysis eligibility decisions were more often made by use of
telemedicine services versus other modalities (96% telemedicine,
83% telephone) with an odds ratio of 4.2. Administration of tPA was
also higher in telemedicine compared with telephone-only consul-
tations (26% versus 24%), but there was no statistically significant
difference in post-thrombolysis hemorrhage.88 This analysis con-
cluded that telemedicine (i.e., video) significantly improved correct
decision making for acute ischemic stroke as compared with tele-
phone. The study authors concluded that ‘‘poor sensitivity of tele-
phone determination of thrombolysis eligibility suggests that
telephone assessments may result in stroke consultants ruling out
patients who should have been treated with tPA.’’88 Similar findings
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regarding the poor sensitivity of the telephone compared with video
were reported in an earlier (published in 2008) study in Germany.89
Similarly, in a 2012 German study, the reliability of brain CT
evaluation by telestroke neurologist was confirmed.90 Two neuro-
radiologists re-examined all CT scans for 536 patients who were
initially assessed by stroke neurologists. The neuroradiologists de-
tected discrepant findings in 8% of the cases, but only 1.7% were
rated as clinically relevant. One patient had evidence of intracranial
hemorrhage, but it was not clear whether that patient received tPA.
The authors concluded that ‘‘stroke neurologists can reliably interpret
the cerebral CT scan of patients with clinically suspected acute is-
chemic stroke in telemedicine in real time.’’90
Intermediate outcomes: event timing. A large number of studies
focused on the critical time intervals from onset of symptoms, to CT
scan of the brain, to treatment and/or transfer, but not always on the
same intervals. We report here on seven such studies that met the
inclusion criteria for our review. None of these studies utilized an RCT
design for the reasons explained earlier.
A study conducted in Germany in 2006 investigated the quality of
procedures related to stroke diagnosis and treatment at community
hospitals via telemedicine (or telestroke) before (n = 299) and after
implementation of telestroke (n = 305).91 More patients were trans-
ferred after than before telestroke (10.3% versus 1.3%) to acute care
hospitals, but all indicators of quality improved, including cerebral
imaging (from 56.5% to 96.4%), speech therapy (from 0% to 58.8%),
and occupational therapy (from 0% to 33.4%). One year after ad-
mission, mortality declined from 18.9% to 17.2%, respectively,
whereas 10.2% and 6.1%, respectively, were living in institutions.
The authors published another report later92 based on the same ex-
perience and reported high levels of satisfaction among clinicians
related to video quality, time consumption, and medical relevance.
Another trend analysis was conducted in Spain using baseline data
for 201 cases in 2006 and 198 cases in 2007 after the activation of the
telestroke program.93 Telestroke consisted of videoconferencing be-
tween the patients at a community hospital and the stroke experts at a
tertiary-care center. Specialists also had access to neuroimaging scans
via the Picture Archiving and Communication System. The historical
comparisons pre- and post-telestroke intervention reveal an increase
in thrombolytic treatment of 4.5%, a decrease in the interval between
onset of symptoms and thrombolytic treatment from 210 minutes to
162 minutes, and a reduction in between-hospital patient transfers.
An Australian study gathered baseline data on 145 patients in the first
or control year and on 130 patients in the second or telestroke year.94 Of
145 in the control group, 36were eligible for tPA,whereas 54 of 130were
eligible for tPA in the intervention group. Of those eligible, 8 patients
received thrombolysis in the intervention group, whereas none in the
control group received the treatment. Time lapse between arrival and CT
scan was similar in both groups, but the use of a telestroke intervention
reduced unnecessary patient transfers and enabled physicians promptly
to identify patients requiring urgent neurosurgical interventions.
A prospective cohort study in Finland, conducted from 2007 to
2009 (published in 2011), compared thrombolysis rates at five
community hospitals (n = 106) via telestroke with those appearing in
person at the emergency room at the hub hospital (n = 985).95 Among
those patients with whom telestroke was used, 57.5% had thrombo-
lytic treatment (a two- to threefold increase). Time to tPA treatment
(onset to treatment time) was 120minutes, and length of consultation
was 25 minutes when it led to thrombolysis and 15 minutes if it did
not. Patients treated with tPA at the community hospitals via tele-
stroke had similar outcomes as those treated at the hub hospital.
A more recently published (in 2014) study in the United Kingdom
used a retrospective case series design to assess the efficacy and
safety of thrombolysis treatment via telephone-based telestroke.96
This study was based on a sample of 2,922 patients who were given
tPA between 2007 and 2010. Of these, 192 were treated with tPA after
an assessment by a remote specialist. The median ‘‘door-to-needle’’
time was 8 minutes faster in the group that was seen in person (65
minutes versus 73 minutes by telephone), but no differences were
observed in neurological outcomes or instance of hemorrhage.
A retrospective record review was conducted in Georgia on 889
telestroke consultations involving 115 patients treated with tPA
during a 20-month period (2011–2012).97 The authors calculated the
time elapsed between emergency department arrival and registration,
start of specialist consultation, CT scan, and thrombolytic recom-
mendation and initiation. The most conspicuous delay occurred
during registration (median of 39 minutes). However, the median
time from emergency department arrival to thrombolysis initiation
was 88 minutes. The main benefit of telestroke was to shorten the
time from emergency department arrival to thrombolysis. Overall,
thrombolysis was initiated within 60 minutes from arrival to the
emergency room and was administered to 13% of the patients.
A prospective analysis of 119 patients demonstrated the benefits of
telemedicine for patients with acute stroke presenting at community
hospitals in Spain (published in 2012).98 This study focused on the
effects of telemedicine in terms of receiving endovascular treatment (as
contrasted with thrombolytic treatment). The telemedicine intervention
consisted of an interactive videoconferencing system that enabled
stroke experts to perform their assessments based on vital signs, in-
terview, and physical examination. A 2-year analysis of patients re-
ceiving urgent endovascular recanalization procedures showed that
telemedicine patients were more likely to receive such treatment than
non-telemedicine patients (20.5% versus 16.4%). This system saved
time in the initiation of interventional therapy, as well as the necessary
processing of informed consent and preparation of the interventional
team before the patients’ arrival at the regional stroke center.
Although the vast majority of telestroke studies relied on quasi-
experimental designs, mostly by necessity, in 2012 a rare RCT,
conducted in Germany, compared diagnosis and treatment of stroke
patients in a mobile stroke unit versus in-hospital.99 Randomization
wasbyweek, alternatingbetweenexperimentalandcontrolgroups, and
was not masked from patients or investigators. The mobile units were
equipped with a CT scanner, laboratory, and telemedicine equipment.
The studywas terminated after interim analysis of 100 cases because it
met prespecified criteria for termination (i.e., the benefits were obvi-
ous). The median time from alarm to therapy decision decreased
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from76minutes to 35minutes. Similar gainswere observed regarding
times from alarm to CT scan, to end of laboratory analysis, and to start
of intravenous thrombolysis. Differences in neurological outcomes
between the two groups at 7 days were not statistically significant.
Health outcomes and cost. Three large-scale studies investigated
health outcomes. In 2009, a prospective nonrandomized study com-
pared a network of five community hospitals with telestroke services
with five matched community hospitals without telestroke, involving
all patients (n=3,060) with consecutive ischemic or hemorrhagic stroke
admitted between 2003 and 2005.100 This German study measured the
effects of telestroke on death, institutional care, and disability. Of 3,060
patients, 1,938 were in the intervention group, and 1,122 were in the
control group. Follow-up rates were high: 97.2% for 12 months and
95.7% after 30 months for death and dependency. The authors found
that death and dependency were significantly lower in the intervention
group and that these differences held across the two follow-up times.
Moreover, these differences remained when the authors controlled for
age, gender, living with a partner, severity of the stroke, and co-
morbidities. The most significant finding was the long-term reduction
in death and disability for those receiving telestroke services.
Another long-term longitudinal study was conducted in Germany
from 2006 to 2009.101 Over a period of 4 years, the number of tele-
consultations increased from 49 in 2006 (technical and organiza-
tional proof-of-concept phase) to 177 in 2007 (implementation stage)
and 577 in 2009, with a total of 1,152 consultations during the study
period. Clinical data were gathered from a nationwide network
consisting of 11 hospitals (six primary-care NeuroNet hospitals and
five tertiary-care stroke centers). In addition, five primary-care
hospitals were used as controls (matched by bed size, departments of
internal medicine, and distance to specialized stroke centers). The
hospitals in the control group benefited from the same manage-
ment system with educational content and peer review but had no
telestroke capability. The NeuroNet concept involved the use of tel-
emedicine (a) to transfer knowledge from stroke centers to primary-
care hospitals, (b) to implement a standardized stroke protocol, and
(c) to provide continuing medical education and peer review in
stroke. Over the course of the study, the use of thrombolytic therapy
increased by 4.8% in NeuroNet hospitals while mortality risk de-
creased by approximately 29% compared with control hospitals.
Between 2006 and 2009, ischemic stroke mortality decreased in all
three hospital cohorts. During the implementation stage (2007 and
2008), both NeuroNet and control hospitals had nearly identical
mortality declines (from 10.5% to 7.5% and 10% and 7.5%,
respectively). Treatment with tPA in NeuroNet hospitals increased
by 1.6% per year, reaching 5.8% after 4 years. Conformity with
protocols for stroke coding (a process variable) also increased
by 45% in NeuroNet hospitals and by 18% in control hospitals.
The authors concluded that ‘‘NeuroNet has substantially contrib-
uted to improving stroke care.and yielded benefits even in
stroke centers.’’101
In 2012 (published in 2013), the cost-effectiveness of telestroke
networks in themanagement of acute ischemic strokewas assessed from
the perspective of a hub-and-spoke hospital network.102 Over a 7-year
period, data from two hub-and-spoke networks (each having one hub
and seven spokes, as a typical telestroke network)—Georgia Health
Sciences University and the Mayo Clinic—were used to compare costs
and effectiveness with and without a telestroke network. The authors
developed a decision-analytic model to compare the costs and effec-
tiveness of the telestroke network. Thismodel traced the critical decision
points in the care process for ischemic stroke patients presenting at a
telestroke network and those without, including both hub and spoke
sites. Outcome measures included teleconsultation rates, thrombolysis
treatment, endovascular therapies, and patient transfers from spoke to
hub hospital. The analysis started with an annual 1,112 patients with
ischemic stroke presenting at emergency departments in the network.
The model predicted 114 fewer patients would be admitted to the hub
each year for those in a network and that 16 additional patientswould be
admitted to each spoke hospital without a network. About 45 additional
patients would be treated with tPA, and 20 more with endovascular
stroke therapy, in the telestroke network. The cost savings estimate
averaged $358,435 annually in the telestroke network and increased
over time for patients treated during the first year from $234,836 at the
end of Year 1 to $393,712 at the end of 5 years. Each spoke hospital
would save $109,080 per year, whereas the hub hospital would bear a
positive cost of $405,804 per year. The authors estimated that cost
sharing between hub and spoke hospitals would result in cost savings of
$44,804 annually for 5 years. Sensitivity analysis revealed robust
overall results. Cost savings were estimated to increase with increases in
the number of spoke hospitals. Cost saving estimates for 5 years ranged
from $8,974 with no spoke hospitals to $2,400,000 for 40 spoke hos-
pitals. In other model scenarios, estimates of cost savings ranged from
$159,718 to $1,359,500 per year from a network perspective.
COPD
COPD is an umbrella term for a group of progressive, debilitating
respiratory conditions characterized by difficulty breathing, lung
airflow limitations, cough, and other symptoms.e Although there is
no consensus on the definition of COPD,104 the Global Initiative for
Chronic Obstructive Lung Disease (GOLD) guidelines define it as ‘‘a
eThe GOLD COPD definition excludes emphasis on ‘‘emphysema’’ and
‘‘chronic bronchitis’’ that have been used in ‘‘many previous definitions.’’103
The 2014 update states that ‘‘emphysema, or destruction of the gas-ex-
changing surfaces of the lung (alveoli) is a pathological term that is often
(but incorrectly) used clinically and describes only one of several structural
abnormalities present in patients with COPD. And, chronic bronchitis, or the
presence of cough and sputum production for at least 3 months in each of
two consecutive years, remains a clinically and epidemiologically useful
term. However, it is important to recognize that chronic cough and sputum
production (i.e., chronic bronchitis) is an independent disease entity that may
precede or follow the development of airflow limitation and may be asso-
ciated with development and/or acceleration of fixed airflow limitation.
(Further).Chronic bronchitis also exists in patients with normal spirome-
try.’’103,p.2
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common preventable and treatable disease,.characterized by per-
sistent airflow limitation that is usually progressive and associated
with an enhanced chronic inflammatory response in the airways and
lungs to noxious particles or gases.’’103 Exacerbations and co-
morbidities contribute to the overall severity and the quality of life in
individual patients. As the incidence of COPD increases, so does the
burden on health services.105
An exacerbation of COPD is an acute event characterized by a
worsening of respiratory symptoms beyond normal day-to-day
variation, typically requiring changes in medication and possibly
hospitalization.106–108 Variable decrease in pulmonary function and
the occurrence of tachypnea (excessively rapid breathing) are typical
in acute exacerbations.103 COPD exacerbations are especially im-
portant because they adversely affect quality of life, take weeks to
resolve, accelerate decline in lung function, and potentially lead to
death. In addition, they are associated with high healthcare cost.
COPD EPIDEMIOLOGY
COPD is a major cause of disability and death throughout the
world, estimated to affect about 10% of the population.109 In the
United States, COPD is the primary contributor tomortality caused by
chronic lower respiratory diseases, which became the third leading
cause of death in 2008 and retained that position in 2010, accounting
for 5.6% (138,080 deaths) of all deaths.110,111
The true prevalence data for COPD in the population is difficult to
obtain. Only two sources—the National Health Information Survey
and the Behavioral Risk Factor Surveillance System—gather infor-
mation on COPD. Both sources use an all-inclusive question in their
surveys that includes emphysema and chronic bronchitis, and data
are self-reported. The Behavioral Risk Factor Surveillance System
estimated 14.7 million adults (defined as ‡ 18 years of age), or 6.2%
of this population, had COPD (including chronic bronchitis and
emphysema) in 2011, whereas the National Health Information
Survey estimated 12.7 million (or 5.5%).112
In 2011, the age-adjusted prevalence for adults was 6.5% (ap-
proximately 13.7 million).113 Hispanics were less likely than whites
and blacks to report having COPD (4.0% compared with 6.3% and
6.1%, respectively). Women were more likely to report having COPD
than men (6.7% versus 5.2%). People without a high school edu-
cation had a prevalence rate of 9.5% compared with 6.8% for those
who completed high school and 4.6% of those who completed some
college. Prevalence rates were much higher (20.9%) among those
unable to work compared with the unemployed (7.8%), retired
(7.6%), homemakers or students (4.9%), or employed (3.8%). A
considerably higher percentage of current smokers reported having
COPD (13.3%) than former smokers (6.8%) or those who never
smoked (2.8%).110 There was considerable geographic variation in
respondents reporting physician-diagnosed COPD (including
chronic bronchitis and emphysema): Kentucky (10.1%), Alabama
(9.9%), Indiana (8.9%), and West Virginia (8.8%) were the states
with the highest reported incidence of COPD, whereas states with
the lowest rates included Minnesota (4.1%), Utah, Washington, and
North Dakota (4.5%).
COPD COST
During the period from 1979 to 2001, data from the National
Hospital Discharge Survey estimated a total of approximately 45
million (8.5% of all hospitalizations in adults > 25 years of age)
discharges were for patients with COPD. Of these, about 36 million
discharges (79%) occurred with COPD as a secondary diagnosis, and
9.8 million (20.8%) occurred with COPD as the primary diagno-
sis.114 In 2008, the estimated direct economic cost of COPD and
asthma was $53.7 billion. These costs included prescription medi-
cines ($20.4 billion), visits to outpatient clinics or office-based
providers ($13.2 billion), hospital inpatient stays ($13.1 billion),
home healthcare ($4.0 billion), and emergency department visits
($3.1 billion).113 In 2010, 133,575 deaths were attributable to COPD.
During the same year, there were 10.3 million (498.4 per 10,000
population) physician office visits, 1.5 million (72.0 per 10,000)
emergency department visits, and 699,000 (32.2 per 10,000) hos-
pital discharges for COPD.113
TELEPULMONOLOGY
Patients with COPD often experience exacerbations in their
symptoms that may require hospitalization. Frequent monitor-
ing is indicated to evaluate their lung function and to assist
in managing their health. Telepulmonology is designed to serve
that purpose, and it consists primarily of two activities: (1) tele-
spirometry for remote measurement of lung function (volume of
air inhaled and exhaled), initially to diagnose COPD and periodi-
cally to ascertain clinical status, and (2) teleconsultations between
primary care providers (physicians and nurses) and pulmonary
specialists for the care and treatment of patients at remote sites.
The goal of teleconsultation is to provide ready access to expert
consultants in areas lacking these resources and also to reduce
unnecessary hospitalization. Telepulmonology can be designed as
an ongoing remote monitoring of COPD in similar fashion to
telemonitoring of CHF.
Evidence of the Impact of Telepulmonology
As with the other two chronic diseases, our review of the evidence
for telepulmonology is focused primarily on the period from 2005
through 2013. Our initial search identified 172 studies. Of these, 17
were included in the final analysis. Here again, our analysis is limited
to robust studies with adequate sample size. COPD is similar to CHF in
terms of its long-term chronic nature that exacerbates with time, its
amenability to treatment, and the feasibility of conducting clinical
trials. Hence, the majority of the studies reported here were based on
RCTs. Most of these studies were focused on COPD, but a few in-
corporated more than one of the three chronic disease entities in this
report. Hence, we tried to include each study only once. Deviations
from this rule are noted explicitly, and the discussion in repeated
cases is very limited. As with telestroke findings, those from COPD
studies are grouped into three clusters of outcomes, but with a slight
variation in headings specific to COPD: (1) feasibility and acceptance
of telepulmonology, (2) use of service, and (3) health outcomes and
cost (Table 3).
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Table 3. Methodology and Findings Pertaining to Chronic Obstructive Pulmonary Disease
LITERATURE SOURCE METHODOLOGY FINDINGS
REFERENCE DATE COUNTRY DESIGN
SIZE
(N) DURATION
TELEMEDICINE
TECHNOLOGY
FEASIBILITY
AND
RELIABILITY
USE OF
SERVICE
HEALTH
OUTCOMES COMMENTS
Raza et al.115 2009 United
States
RCC/PCC 314 7 years VTC Yes 8% required
in-person visits
NM Patient travel avoided;
patient satisfied
Bonavia et al.116 2009 Italy OS 937 2 years TS via T Yes NM O High GP acceptance of TS
Averame
et al.117
2009 Italy OS/PCC 638 NR TS via T Yes NM TS used in diagnosis
and airway
management
Encourages testing of
smokers without
symptoms
Bernocchi
et al.118
2012 Italy OS 474 6/12 months T, POx Yes NM HPS Growing need for home
management
Whitten and
Mickus119
2007 United
States
RCT 161 11 weeks VTC Yes NM HPS Small n
Vitacca et al.120 2009 Italy RCT 240 1 year T, POx Yes - 36%
hospitalizations;
- 65% GP calls
- 71% acute
exacerbations;
telemedicine greater
care advantage
Overall costs 33% less
with telemedicine
Vitacca et al.121 2010 Italy OS 396 5 years NC, POx Yes Nurse time
increased; MD time
decreased
— 39% cost savings
Dinesen et al.122 2012 Denmark RCT 111 10 months WTM, VTC Yes Lower
hospitalization
— Small sample size
Sorknaes
et al.123
2013 Denmark RCT 266 26 weeks VTC Yes O 1 week of
teleconsultations
post-AECOPD, no
effect
Patients had ECOPD; only
1 week of telesupport
Sorknaes
et al.124
2011 Denmark NRCT 100 28 days VTC Yes NM HPS VTC showed protective
factor
Pinnock et al.125 2013 United
States
RCT 256 12 months HTM Yes Not effective with
ECOPD
O Speculates positive results
of other studies due to
clinical service
Strickland
et al.126
2011 Canada CNRA 409 6 months VTC Yes Reduced and
delayed re-
admisions/LOS
QoL up Lower re-admission rate
(12% versus 22%)
de Toledo
et al.127
2006 Spain RCT 157 1 year Call center,Web,
HTM, VTC
Yes Lower number
of re-admissions
— Value in integrated
telemedicine case
management
Gellis et al.128 2012 United
States
RCT 102 12 months T, HTM Yes — Health, social
functioning,
depression, ER visits
all improved
LOS not significant at
12 months
Pedone et al.129 2013 Italy RCT 100 9 months POx, T, wristband
vitals monitor
Yes LOS longer for
intervention group
Med use,
hospitalization,
exacerbation risk all
lower
Vitals collected every
3 hours
Cardozo and
Steinberg130
2010 United
States
OS 851 60 days HTM (embedded in
EMR)
Yes Positive
telemedicine
benefit for
hospitalization, ER
visits
Improved survival Re-hospitalization rate
13.9% and ER visits 29%
(versus national rates of
56.4% and 45%,
respectively)
Thijssing
et al.131
2013 The
Netherlands
OS 1,958 3.5 years TS Yes Physical referrals
reduced 27%
TPC increased
pulmonologists’
referrals 18% where
needed
Unneeded referrals
reduced 68%
AECOPD, acute exacerbated chronic obstructive pulmonary disease; CNRA, comparative nonrandomized analysis; ECOPD, exacerbated chronic obstructive pulmonary disease;
EMR, electronic medical record; ER, emergency room; GP, general practitioner; HPS, high patient satisfaction; HTM, home telemonitoring; LOS, length of stay; NM, not
measured; NR, not reported; NRCT, nonrandomized controlled trial; O, neutral outcome; OS, observational study; PCC, prospective case control; POx, pulse oximeter; QoL,
quality of life; RCC, retrospective case control; T, telephone; TPC, telepulmonary consultations; TS, telespirometry; VTC, video teleconference; WTM, wireless telemonitoring.
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FEASIBILITY AND ACCEPTANCE
One of the earlier studies (published in 2009) was observational,
and it described a pulmonary telemedicine model at a Veterans
Affairs hospital in Milwaukee, WI.115 In total, 314 patients received
telemedicine consultations for abnormal radiology (38%), COPD
(26%), and dyspnea or shortness of breath (13%). Physical exami-
nations were conducted mostly by telemedicine nurses or respira-
tory therapists (90% of the cases). Telemedicine consultations
resulted in changes in patient management in 41% of the cases, and
only 8% required an in-person visit. In addition, over the 5-year
period of the study, telepulmonology saved patients over an esti-
mated 294,000 miles of travel, thereby reducing carbon footprint.
The authors reported that this intervention was not only feasible
from a technical perspective but also improved access to subspe-
cialty care. Moreover, patients were satisfied with their tele-
medicine experience.
Telespirometry has been investigated for its potential in assisting
GPs in managing their patients with COPD. In 2009, an Italian study
of 937 GPs who, over a 2-year period, received the results of tele-
spirometry performed on over 20,000 patients (conducted by pa-
tients with tracings sent by telephone).116 Data indicated that 70%
of the tests met the criteria for good or partial compliance in per-
forming the procedure, allowing abnormalities to be detected in
40% of the tracings. Only 9.2% could not be evaluated. Overall, the
authors concluded that telespirometry was well accepted by these
Italian GPs.
A somewhat similar study was conducted by the same authors
(published in 2009),117 wherein 638 GPs were trained to perform
telespirometry on four sets of subjects: (1) smokers and ex-smokers
without respiratory symptoms, (2) patients with respiratory
symptoms but not diagnosed, (3) patients diagnosed with asthma,
and (4) patients diagnosed with COPD. All traces were interpreted
by specialists. In addition to confirming the feasibility of tele-
spirometry in a primary care setting, this study challenged the
strategy of denying spirometry for individuals without respiratory
symptoms—if they were smokers. The authors argued that the
finding of airflow obstruction from spirometry may be used as a
deterrent against smoking. At the same time, a significant pro-
portion (23%) of patients already diagnosed with COPD had normal
spirometric values.
The experience of a regional network in Lombardy, Italy, dem-
onstrated the feasibility and patient acceptance of telemedicine for
managing heart failure and COPD (published in 2012).118 In total, 474
patients with COPD received remote consultations. More than 95% of
patients were satisfied with the service, and 98% were satisfied with
the nurse-tutor.
Patient perceptions of a home telemedicine program for COPD and
CHF patients were compared with those of a control group receiving
usual care.119 No significant differences were observed between pa-
tients in the intervention group and those in the control group with
regard to perceptions of health and well-being. However, the small
sample size for patients with COPD (28 of 161 patients in the study)
precludes any generalization regarding COPD.
EFFECTS OF TELEPULMONOLOGY ON USE OF SERVICE
Two reports were published from one program in Italy, labeled as
‘‘Tele-assistance in COPD.’’120,121 The first was an RCT of 240 patients
allocated to either an intervention or a control group and observed
over a 1-year period,120 and the second was an observational study of
396 patients over a 5-year period.121
In the first study, in total, 866 patients were discharged from the
respiratory unit, but only 240met the selection criteria for the clinical
trial. Although patients with worsening symptoms had a significantly
higher number of re-hospitalizations, as would be expected, the re-
sults from the RCT revealed no significant differences in mortality
between the control and intervention groups. However, compared
with the control group, those in the intervention group experienced
fewer hospitalizations ( - 36%), urgent calls to the GPs ( - 65%), and
acute exacerbations ( - 71%). Cost savings were estimated at 33% per
patient after discounting the cost of the telepulmonology system. Of
interest also is that these benefits were still significant among pa-
tients suffering from chronic respiratory failure who were on oxygen
or home ventilators.
The second article was based on an observational study over a 5-
year period (2004–2009) of patients with chronic respiratory failure.
It reported on trends over time among those having the telemedicine
intervention, as well as effects on staff activity and salary cost. The
trend data showed a shifting in costs, with an overall decrease in
physician time and an increase in nurse time, thereby resulting in cost
savings of 39%.
Somewhat similar findings were reported in 2012 from a Danish
RCT (n = 111) that investigated the use telemedicine for COPD.122
Patients were recruited from a health center, a general practice, and a
pulmonary hospital ward. Both intervention and control groups were
observed over a 10-month period. The intervention group had a
lower hospital admission rate compared with the control group (0.49
versus 1.17). Other outcome measures were not statistically signifi-
cant, likely because of a small sample size.
A more recent (published in 2013) RCT (n = 266) in Denmark in-
vestigated the effect of daily teleconsultations for 1 week between
specialized nurses and patients who had severe COPD and had been
discharged from the hospital after an exacerbation.123 Patients in
both the intervention and control groups were offered outpatient
clinic consultations with a nurse at 4- and 12-week intervals. The
intervention groupwas offered daily consultations by video for about
7 days (range, 5–9 days) that included, when indicated, smoking
cessation, physical training, and rehabilitation followed by telephone
consultations. The study found no significant differences between the
two groups with regard to mortality or hospital re-admissions. The
authors concluded that the limited (1-week) teleconsultations be-
tween hospital-based nurses and patients with severe COPD did not
significantly reduce readmissions or affect mortality. Yet, different
findings were reported by the same senior author (with different co-
authors) about 1 year earlier.124 This was an interventional study in
which all patients were consecutively assigned to the intervention or
control group on the basis of the municipality of their residence.
Very similar protocols were used. Here, the authors found that
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videoconferencing was significantly related to reductions in early re-
admission (16% in the intervention group versus 30% in the control
group).
A 2013 study of a multicenter RCT (n = 256) conducted over a 12-
month period among individuals with a history of hospitalizations,
however, did not find that videoconferencing postponed hospital
admissions or improved the quality of patients’ lives.125 The inter-
vention consisted of daily patient responses entered on a touchscreen
device to questions about symptoms and use of treatment and oxy-
gen saturation. The study was focused on investigating the effects of
telemonitoring technology. The intervention and control groups
were both provided with the same clinical care (i.e., a written man-
agement plan, antibiotics, and steroids). The study concluded that
among patients ‘‘with a history of admission for exacerbations of
COPD, telemonitoring was not effective in postponing admissions
and did not improve patients’ quality of life.’’125 The investigators
speculated that the positive effects of telemonitoring reported in
earlier studies may have been due to enhancements of clinical service
in the telemonitoring group.
HEALTH OUTCOMES AND COST
A Canadian comparative nonrandomized analysis was conducted
on a group of 147 COPD patients who participated in an 8-week
pulmonary rehabilitation program via telemedicine and a group of
262 patients who received the same educational content via a stan-
dard outpatient hospital-based program.126 Both groups had similar
improvements in quality of life and exercise capacity, and these re-
sults were sustained over a period of 6 months. The authors con-
cluded that telehealth rehabilitation was ‘‘an effective tool for
increasing COPD pulmonary rehabilitation services.’’126
In 2006, an RCT (n = 157) conducted in Spain investigated the
effects of an integrated telemedicine system on hospital re-admission
rates and mortality.127 The telemedicine service consisted of a call
center, an application server, and an educational server, all con-
nected to the patients’ homes. The application server included three
different applications: a Web-based Patient Management Module, a
telemonitoring module, and a home visit server. Care was coordi-
nated by a specialized nurse (case manager) and involved a specialist
and other professionals. Both groups received a single educational
session and a single home visit. Patients in the control group did not
have access to the call center. The authors found that the integration
of telemedicine with case management ‘‘increased the number of
patients who were not readmitted (51% intervention versus 33%
control), is acceptable to professionals, and involves low installation
and exploitation [utilization] costs.’’127
The following two studies had samples fewer than our suggested
standard of 150 cases. Nonetheless, they are included here because of
some unique features. A small RCT (n = 102) involving both heart
failure and COPD patients was conducted in 2012.128 The technology
included a small table-top in-home monitor and a central station
located at the home health agency. Data were transmitted via a
telephone line through a secure link. The intervention group had
better health outcomes (general health, social functioning, and re-
duction in depression). Additionally, they had fewer visits to the
emergency department and a general trend of fewer hospital days
(but the number of days hospitalized did not reach significance at 12
months).
Another small RCT (n = 100) from Italy investigated the effects of
telemonitoring on respiratory outcomes in an elderly population (65
years of age and older).129 The intervention group received a wrist-
band with sensors for heart rate, physical activity, near-body tem-
perature, and galvanic skin response. The wristband was also
connected to a pulse oximeter. A cellular telephone received and
transmitted the data to a monitoring system. The system performed
measurements every 3 hours. Data were gathered automatically, but
the patient had to wear and turn on the wristband. A sound reminded
the patient to wear the pulse oximeter when the measures were to be
collected. After 9 months, the intervention group had a lower rate of
exacerbations requiring change in medication and hospitalization
(incidence rates of 28% versus 42% per year) and a 33% reduced risk
of exacerbation. However, the average length of stay in the inter-
vention group was longer, suggesting that the threshold for hospi-
talization was lower in the control group.
Two observational studies may be worth reporting here, primarily
because of their large samples. The first documented the results of a
home-based case management telemedicine program for COPD over a
2-month period (n= 851) in Michigan.130 Although not definitive, the
findings suggest some positive benefits from telemedicine in terms of
hospitalization, emergency visits, and mortality. The second obser-
vational study was conducted in The Netherlands (n = 1,958) and as-
sessed the effect of telepulmonology on quality and efficiency of
care.131 All GPs in The Netherlands who had a spirometer and com-
puter access were eligible to use telepulmonology and were linked
with pulmonologists. Over a 3½-year period, 158 GPs consulted with
32 pulmonologists in this national Web-based system, generating
1958 teleconsultations for 1,828 patients (ranging in age from 6 to 91
years). Of these, 23% of patients were diagnosed with COPD. The
majority of the consultations (69%) asked for advice. Eighteen percent
of the telepulmonology consultations resulted in a physical referral of
patients who would not have been referred without this system. When
asked whether the teleconsultation with the pulmonologist was
helpful, only 4% of GPs gave a negative answer. About one-third
(31%) of the telepulmonology patients were referred for direct care
services, and 68% of these consultations actually prevented a referral.
Cost Studies
The initial literature search yielded for cost studies yielded 499
articles. Of these, 14 were used in the final analysis. Although sev-
eral studies cited above included some economic data, typically in
terms of use of service (hospitalization, emergency department visits,
etc.), we include here a special section on studies that focused on
economic analysis. The methods include cost-benefit analysis, cost-
effectiveness analysis, cost minimization analysis, and return on
investment. Because telemedicine research cost analysis does not
adhere consistently to these traditional methodologies, we include a
brief explanation for each:
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. Cost-benefit analysis is based on converting all inputs and
benefits (or outputs) into monetary terms as a basis for com-
paring the merits of two or more programs, interventions, or
projects. It provides a concrete basis for determining whether
the benefits of a given intervention (or policy) outweigh its cost.
The main impediment in using cost-benefit analysis in health-
care is the difficulty of achieving consensus on translating
benefits such as years of life or disability into dollar amounts.
. On the other hand, in cost-effectiveness analysis the costs are
monetary, whereas the outcomes are non-monetary. It can
provide a comparison of the relative costs of two interventions
for achieving the same result, such as a medical visit or a given
state of health.
. Cost utility analysis is a particular type of cost-effectiveness
analysis that uses quality-adjusted life years as an outcome.
. Cost minimization analysis (or cost saving analysis) is con-
cerned with finding the least costly alternative to producing a
medical visit or an episode of care, assuming health outcome is
the same.
. Finally, return on investment divides the total monetary benefit
by initial investment and subsequent cost, expressed as a per-
centage or ratio. However, return on investment may include
non-monetary benefits that may be difficult to quantify, such as
contribution to public service, enhanced reputation, and client
satisfaction.132 Downstream revenue from enhanced reputation
can be measured in quantitative terms, but it is often difficult to
trace. Nonetheless, despite the inherent importance of return on
investment to health systems or private investors, we did not
find robust return on investment studies for this report.
It should also be pointed out that the cost studies reviewed here
were not all based on a single perspective. They assumed a societal
perspective, a health system perspective, or a payer perspective.
Although not included in this review, there also is a substantial
research literature on telemedicine costs in various settings (primary
care, healthcare networks, etc.). Examples include psychiatry133
(including depression134–136 and dementia137), dermatology,138–144
sleep apnea,145 orthopedics,146 nephrology,147 diabetes,148–152 can-
cer,153–155 otolaryngology,156 lifestyle (smoking, diet, obesity157),
tuberculosis,158 high-risk pregnancy,159 intensive care,160 and neo-
natal care,161 as well as other applications.
The following analysis is based on 14 cost studies (Table 4) dealing
with one or more of the target chronic diseases in this article and is
organized on the basis of the particular cost method used in the study.
THE EVIDENCE RELATED TO COST
Three studies that investigated cost-effectiveness of heart failure
telemonitoring, telestroke, or a combination of chronic diseases were
reviewed earlier and will not be repeated here. In chronological order,
these were the Veterans Affairs CCHT program for Veterans with
chronic conditions by Darkins et al.48 (published in 2008), the Tel-
Assistance program for COPD by Vitacca et al.120 (published in 2009),
and the Georgia/Mayo Clinic hub-and-spoke networks serving is-
chemic stroke patients by Switzer et al.102 (published in 2013).
All three studies reported positive findings regarding the cost-
effectiveness of the respective telemedicine interventions. The find-
ings were not uniformly positive, however. A British study by
Henderson et al.162 (published in 2013) reported neutral findings.
COST-BENEFIT ANALYSIS
Only two of the cost studies meeting the criteria for inclusion (i.e.,
having a focus on CHF, stroke, and/or COPD) used variants of cost-
benefit analysis. The first was discussed in two publications from a
telecardiology project in the State of Minas Gerais in Brazil (pub-
lished in 2011 and 2012) and consisted of a cost-benefit analysis of
conducting an ECG via telemedicine versus in-person.163,164 The
authors calculated the opportunity cost of transportation, food, and
wage loss, as well as the specific charges for the ECG and consultation
with a specialist.163 Input costs included wages, equipment, im-
plementation, maintenance, and assessment. The cost estimate for
transmitting ECG tracings together with a consultation with a car-
diologist was 28.92 R$ (Brazilian Reals, equivalent to about $13 U.S.),
compared with a range of 30.91–54.58 R$ (equivalent to $13.90–
24.54 U.S.) for a patient referral to have the ECG in another city. A
year later, another report from the same project164 showed sub-
stantial savings in travel costs. Over a 5-year period, the investment
of $9,000,000 U.S. resulted in over twice the savings ($20,081,840
U.S.) for the public health system.
In 2012, a matched-pair analysis (essentially a case–control study)
of 281 program participants receiving an intervention consisting of a
decreasing intensity of nurse-supervised telephone calls were com-
pared with a control group of 843 cases (a ratio of 1:3) matched on
demographics and morbidity status.165 In the intervention group,
patients were encouraged to perform self-measurements (blood
pressure, pulse, weight) via portable devices, and they received a
mobile phone to transmit the data to the clinic if a telephone was not
already available in the household. Monetized cost data for the two
groups (including medication, hospitalization, therapeutic aids, total
treatment, and mortality) were compared over a 1-year period. Al-
though the intervention group had up to a 25% reduction in total
cost, patients with mild symptoms and slight limitation—NYHA
Class II—had the most gains. More severe classes (III and IV) had a
slight cost advantage. Overall, patients in the intervention group
‘‘experienced a reduced number of hospital stays, optimized medical
therapy, [achieved a] better quality of life, and [had] a reduction in
mortality.’’165
COST-EFFECTIVENESS ANALYSIS
In total, six studies met the criteria for inclusion based on the use
of a cost-effectiveness analysis. In 2008, a large RCT (n = 1,069) U.S.
study investigated the cost-effectiveness and health outcomes of
telephonic disease management for heart failure.166 Patients were
enrolled for a period of 18 months and randomized into three groups:
usual care, disease management, and augmented disease manage-
ment. All patients were assigned a disease manager, a registered
nurse who provided education and medication management. Those
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Table 4. Methodology and Findings Pertaining to Cost
LITERATURE SOURCE METHODOLOGY FINDINGS
REFERENCE DATE COUNTRY DESIGN SIZE (N)
DURATION
(MONTHS) TECHNOLOGY COST BENEFIT
COST-
EFFECTIVENESS COMMENTS
Henderson
et al.162
2013 United Kingdom CRCT 965 12 T, HTM — Neutral Neutral to equivocal
findings for QALY and cost
Andrade
et al.163
2011 Brazil CBA 82 towns 18 ECG — HTM, 28.92R$
(versus 31–55R$)
Cost calculation: travel,
food, lost wages, ECG
charges
Alkmim et al.164 2012 Brazil OS 825,349 ECGs 60 ECG Cost ($9M); savings
($20M)
— 2 · health system cost
benefit
Sohn et al.165 2012 Germany PCC 1,124 12 Cell phone 25% cost reduction — Decreasing intensity of
nurse calls; QoL up, hospital
stays/mortality down, NYHA
Class II–IV gains
Smith et al.166 2008 United States RCT 1,069 18 T — Telemedicine
effective but costly
—
Elliot et al.167 2008 United Kingdom RCT 500 1 T — Lower costs after 2
months
Pharmacy/medications
compliance, fewer adverse
events
Salvador
et al.168
2008 Spain NRP 108 12 Internet
monitoring
— Hospital visits
lower, QoL higher
Reduced oral anticoagulant
therapy management costs
Datta et al.169 2010 United States RCT 588 24 T — No significant
differences
Called for 1 week, then
every 2 months for 24
months; nurse BP
management
Wennberg
et al.170
2010 United States RCT 174,120 12 T — 10.1% admission
cost reduction
Lower medications/scripts
$ cost (3.6%); telehealth
coaching (costs, self-care,
behavior, etc.); program
cost < $2.00/person/month
Minetaki
et al.171
2011 Japan CBA 408 48 T, HTM — — Frequency/duration of
telemedicine decreased use
of output services, travel,
worsening patient
symptoms
Brunetti et al.172 2014 Italy CA 109,750 12 ICD/ECG triage — — Cost savings of e8.10–
38.50/case
Calo et al.173 2013 Italy RCT 233 12 T, HTM — — HTM, hospital visits/LOS
shorter (47 minutes versus
86 minutes); HTM savings:
$51/patient/year for
hospitals, $190/patient/year
for patients
Zanaboni
et al.174
2013 Italy RCT 200 16 ICD — No health system
cost savings
Significant remote patient
cost reduction; 0.065 QALY
gain
Chen et al.175 2013 Taiwan QE 141 6/6 T — 48% cost decrease
(from $937 to
$492/month)
CHF telemedicine service,
hospital admissions/stay
down; no difference in ER
visits
BP, blood pressure; CA, cost analysis; CBA, cost benefit analysis, ICD, implantable cardiac defibrillator; CHF, congestive heart failure; CRCT, cluster randomized trial; ECG,
electrocardiogram; HTM, home telemonitoring; ICD, implantable cardiac defibrillator; NC, nurse calls by telephone; NRP, nonrandomized prospective study; NYHA, New
York Heart Association; OS, observational study; PCC, prospective case control; QE, quasi-experimental; QoL, quality of life; QALY, quality-adjusted life year; RCT,
randomized controlled trial; SR, self-reporting; T, telephone.
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in the augmented disease management group also received devices
for self-monitoring (electronic blood pressure monitor, pulse oxi-
meter, and a wristwatch activity monitor). However, data for the two
intervention groups (disease management and augmented disease
management) were combined in a pooled analysis because their
outcomes were similar. Of the original sample, 30% did not complete
the study, missed one or more visits, were lost to follow-up, or died.
An ‘‘intent-to-treat’’ methodology was used to estimate cost and
survival data for the entire sample. The resulting difference in total
costs between the two disease management groups and the usual care
group could be almost entirely attributed to the costs of the inter-
vention itself. At the same time, the analysis showed significant
survival advantage among the combined intervention groups (79.4
days) compared with all patients (17.4 days). Even those in the in-
tervention groups who were acutely ill (NYHA Classes III and IV) had
survival of 47.7 days. There was also evidence that patients in the
non-augmented disease management group received more care, with
higher costs for emergency room visits, hospital admissions, outpa-
tient visits, and drugs. The authors concluded that although the in-
vention was effective, it was also costly to implement.
An RCT (n = 500) conducted in the United Kingdom assessed the
cost-effectiveness of a telephonic pharmacy intervention on com-
pliance with prescribed medications.167 After a 4-week follow-up,
patients receiving telephone calls from the pharmacist were more
likely to comply with their medication regimen and also experienced
fewer medication-related adverse events. After 2 months, the same
group had lower costs.
A nonrandomized pilot study in Spain (n = 108) compared an
Internet-based monitoring intervention with usual care for patients
on oral anticoagulant therapy (typically prescribed for heart fail-
ure).168 The measurement for calibrating the optimal dose was
standardized by the World Health Organization in 1983 as the In-
ternational Normalized Ratio (INR) to minimize adverse effects of
anticoagulant therapy. The INRs were similar between the interven-
tion and control groups. However, quality of life measures were
higher and outpatient visits were substantially lower in the inter-
vention group compared with the control group.
In 2010, an RCT at the Durham, NC Veterans Affairs Medical
Center (n = 588) evaluated the economic effects of telephone calls by
nurses in a program designed to improve blood pressure control
among hypertensive primary care patients.169 The nurses used edu-
cational scripts and tailored algorithms to fit individual patient
needs. Telephone calls were initially made 1 week after randomiza-
tion and subsequently every 2 months for 24 months. Patients in the
control group were also contacted at 6 and 24 months by their pri-
mary care provider. The direct and indirect costs of the twomodalities
were calculated, and the total cost difference between the two groups
was not statistically significant.
In the same year, a very large U.S.-based RCT (n = 174,120) in-
vestigated the economic effects of a telephone-based care manage-
ment intervention on medical costs and healthcare resource use.170
Health coaches contacted patients with high-cost chronic conditions
to instruct them about shared decision making, self-care, and be-
havioral change. Patients were randomly assigned to telephonic case
management plus enhanced support (coaching) or only telephonic
case management. A 10.1% reduction in annual hospital admissions
accounted for the majority of the cost savings for patients in the
group that received enhanced support. They also had 3.6% lower
medical and prescription drug costs.
In 2011, matched panel data of medical expenditures for 408
residents in Fukushima Prefecture, Japan, were analyzed to ascertain
the cost effects of e-health in relation to the duration and frequency
of the intervention.171 Investigators found that the frequency and
duration of e-health use decreased travel expenses and the use of
outpatient services by preventing exacerbation of symptoms.
In the remainder of this section, we report on four studies that were
published in 2013–2014: three from Italy and one from Taiwan. The
Italian studies focused on cost implications of ECG triage and im-
plantable ICDs. The first was a cost analysis from the perspective of a
regional healthcare system.172 It was based on the costs incurred by
all patients who called the local emergency service in 2012 and had a
pre-hospital triage for those with suspected acute cardiac disease
(n = 109,750). The pre-hospital ECGs were read by a remote cardi-
ologist. Cost savings were calculated by subtracting the cost of the
pre-hospital triage. The cost for a single ECG/consultation was
e16.70 ($22.70 U.S.), compared with a regional rate list of e24.80–
55.20 ($33.81–75.25 U.S.) for emergency department charges. Hence,
the telemedicine consultation resulted in cost savings of e8.10–38.50
($11.04–52.48 U.S.) per case.
The second was an RCT (n = 233) comparing the costs of remote
monitoring of implantable defibrillators with those of conventional
in-hospital quarterly follow-ups over a 12-month period.173 Costs
were calculated for patients and providers separately, excluding the
cost of the device. Patients in the remote monitoring group were
scheduled for one in-hospital visit per year unless more visits are
indicated by device alarms or the patient’s clinical status. Patients in
the remote monitoring group had fewer hospital admissions and
substantially shorter duration of follow-up visits compared with the
control group (47 minutes versus 86 minutes). The authors concluded
that if the costs of the device and service were not charged to patients
or providers, patients could save $190 by using remote monitoring,
and hospitals could save an additional $51 per patient per year.
Another cost analysis of implantable defibrillators was based on
an RCT (n = 200).174 Patients with implantable defibrillators with
wireless transmission were randomized between remote monitoring
and conventional care and were followed up for 16 months. No
significant cost savings for the healthcare system were observed, but
there was a significant reduction in cost for patients. Also, patients in
the remote arm gained 0.065 quality-adjusted life-years compared
with those in the standard arm. A cost savings of e888.10 ($1,210.66
U.S.) was realized per patient over the 16-month study period.
Finally, a 2013 quasi-experimental study in Taiwan investigated
the clinical outcomes and cost-effectiveness of a telemedicine service
for older adults with cardiovascular diseases.175 This study followed a
single group pre–post design. In total, 141 consecutive patients with
cardiovascular disease were recruited. Of these, 93 were 65 years of
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age or older, and 48 were younger than 65 years. The intervention
included real-time transmission of biometric measures, telephone
exchanges for communication and health promotion, and full-time
case managers and cardiologists. The telemedicine intervention re-
sulted in significant reductions in all-case admission rates and hos-
pital stays, an increase in outpatient visits, and no difference in
emergency visits. The total cost of all-cause healthcare (comparing
costs 6 months before and 6 months after the intervention) decreased
by 48%: from $937 to $491.52 per month.
Summary and Conclusions
This article assessed the evidence concerning the effects of tele-
medicine on healthcare quality, access, and costs vis-a`-vis three of
the leading causes of death in the United States: CHF, stroke, and
COPD. Conclusions were based on a systematic review of the pro-
fessional literature published from 2000 to early 2014, selected on the
basis of scientific merit. Of the studies that met the minimum criteria
for inclusion, 19 dealt with CHF, 21 with stroke, and 17 with COPD.
An additional set of 14 studies investigated cost.
CONTEXTUAL AND METHODOLOGICAL ISSUES
A careful review of the published literature reveals significant
variations in the methodologies used as well as the outcomes mea-
sured. These include research design and sample size, as well as the
specific attributes of the intervention itself, such as technological
configuration, provider mix, patient mix, program content, fre-
quency, and duration. The technologies used ranged from telephones
(including smartphones) to videoconferencing, from manual to au-
tomated data entry, from point-to-point connections to dedicated
networks to the Internet, and from autonomous equipment to
wearable or implantable devices, some with remote diagnostic cap-
abilities. Some systems linked patients with providers, whereas others
linked providers with other providers. For stroke in particular, some
included specially equipped emergency mobile units.
Other significant aspects of the various telemedicine interventions
included the types of providers and patients. For instance, nurses,
registered nurses, and specialized nurses were, in most instances, the
‘‘front line’’ managers/contact persons regardless of the level of
technology used. And, where required, technicians set up remote
monitoring equipment in patients’ homes and trained patients in
their use. In two instances,54,96 remote telemonitoring cases were
managed by specialist physicians. The patient populations varied in
age, severity of illness, comorbidity, and location. Finally, issues of
program fidelity, maturation, and bundling add another layer of
complications that may be important to consider. The variations from
one study to another significantly constrain our ability to draw
conclusions that can be generalized. At the same time, it must be
recognized that a homogeneous telemedicine landscape now or in the
future is beyond reasonable expectation. Indeed, we might anticipate
even greater diversity as the implementation of telemedicine ma-
tures. Therefore, the heterogeneity of telemedicine applications re-
viewed here does provide a window into telemedicine’s impact across
the complex ‘‘real world’’ of current programs designed to manage
chronic illnesses, as well as the specific application configurations
that had positive impacts. Because of these variations, the findings
and conclusions must be viewed from the perspective of the meth-
odology used in each study. Nonetheless, there are significant areas
of agreement on several dimensions.
THE EVIDENCE
The preponderance of evidence from studies using rigorous re-
search methods points to beneficial results from telemonitoring in its
various manifestations, albeit with a few exceptions. Generally, the
benefits include reductions in use of service: hospital admissions/
re-admissions, length of hospital stay, and emergency department
visits typically declined. It is important that there often were re-
ductions in mortality (decreases ranging from 15% to 56%). Some
studies reported neutral or mixed findings. For example, there may
have been no decrease in hospital admissions, but a reduced length of
stay or a corresponding increase in outpatient visits. Some investi-
gators reported little change in health services utilization but re-
ductions in mortality. One study61 reported an increase in mortality
among frail elderly patients but no increase in use of services. These
findings and explanations for them are reported in detail in the main
body of the report. In totality, however, the findings provide useful
insight and notable trends in telemedicine interventions in the
management of three major chronic diseases.
The implications of the evidence can be summarized at several
levels of generality. At the most general level, the telemedicine in-
tervention in chronic disease management consists of a set of inputs
and outputs. Telemedicine changes the inputs of the traditional
medical care process. Patients consequently are engaged in manag-
ing their own health in an increased number of phases of the care
process. They are encouraged to adopt healthy lifestyles and to
manage their medications, and they are provided with coordinated
remote and local continuous care management. The capacity for
early intervention and rapid response associated with telemedicine,
plus empowered, educated, and engaged patients, can have signifi-
cant effects on the outputs. Costs frequently are reduced by avoiding
unnecessary services. Moreover, the costly complications of chronic
illness may be reduced, yielding improved health outcomes among
more informed patients, who are more likely to engage in positive
health behaviors and to adhere more closely to prescribed medical
regimens and self-care guidelines. In brief, the extent to which the
inputs in the care process are changed is likely to have a direct
bearing on the nature and magnitude of changes in outputs.
At the second lower level of generality, there are five notable
interactions between aspects of the intervention and observed find-
ings from the studies:
1. The technological configuration. The type and complexity of
the technology can have an independent effect on the out-
comes under investigation. For example, in telestroke, visual
clues and the ability to interact virtually with the patient, to-
gether with neuroimaging to assess the appropriateness of
administering tPA, provided significant information to the
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consultant in making a diagnosis and in guiding the care
process from a distance. Telephone-only discussions were less
effective. However, the technology has been evolving rapidly,
and it may be the case that advances in mobile telephony with
high-resolution video and audio connectivity will result in
increased telephone utility. Wearable sensors, implantable
devices, and smartphones have produced demonstrable effi-
ciencies in the delivery of service. These are less cumbersome
for older patients with multiple health issues and are likely to
provide more reliable information than patient self-reporting.
2. Patient mix. When highly skewed toward a sicker patient
population, such patient characteristics as age, severity of ill-
ness, and comorbidities can mask the true effects of the tele-
medicine intervention in a way that is less likely when
telemedicine is used with a healthier group of patients, without
complex comorbidities. Frail elderly patients suffering from
several serious chronic illnesses are not likely to use or benefit
from this technology as it has thus far been implemented.
In addition to a generational difference, many patients lack the
necessary manual dexterity, patience, or inclination to rely on
devices to manage their deteriorating health unless, of course,
these devices are totally unobtrusive and simple to operate. Itmay
be, however, that telemedicine could be beneficial to geriatricians
and otherswho specialize in treating the elderly, allowing them to
organize the treatment of complex patients with multiple diag-
noses, to improve theirmanagement at timesof care transitions176
(see also Chugh et al.177), and possibly to facilitate their under-
standing and adherence to discharge instructions.
If the sampling frame is diverse, randomization of subjects
cannot fully rectify the problem, especially when investigators
attempt to impute values of missing data for nonparticipants and
dropouts, as sometimes occurs when an ‘‘intent-to-treat’’ analysis
isused. For example, imputingutilizationdataafter patientsdie or
drop out of a study is at best an imperfect interpolation, based on
the highly questionable assumption that values are missing en-
tirely at random.
3. Patient engagement. A related phenomenon pertains to the
level and intensity of patient participation in the intervention.
One large study59 suggested that ‘‘patient engagement’’ had a
significant effect in terms of use of service and cost. Obviously,
the true effects of the intervention can be manifest only when
it is administered in full fidelity.
4. Provider mix. Whereas nurses served as the ‘‘front line pro-
fessional’’ in the vast majority of studies, they were not as-
signed the same level of responsibility in decision making. It
seems that they performed best when an explicit protocol in-
cluding software was followed. In one instance,54 where
physicians were in control of the telemedicine intervention,
more patients in the intervention group were hospitalized than
those in the control group.
5. Truncated comparison. Some studies enhanced the services
available to the control group—normally referred to as ‘‘usual
care’’—in order to isolate the specific effects of the technological
component per se, by providing patients ready access to nurses
and physicians on demand and giving them weight scales and
other devices, in other words, equating the experimental and
control groups in every way except for electronic connectivity.
This ignores the fact that, under normal conditions (outside of
participating in a study), patients would not have these additional
benefits. Although this approach may enable a more targeted
testing of specific hypotheses regarding telecommunications, it is
not an appropriate control for a ‘‘bundled’’ innovation that serves
as a substitute for in-person care in an integrated system.
At a more detailed ‘‘fine-grained’’ level, the main body of this
article provided the key findings from each of the studies that met the
minimal inclusion criteria concerning the effects of telemonitoring
among persons with CHF, stroke, or COPD. An empirical assessment
of these findings reveals significant concurrence on positive effects
vis-a`-vis the following: (1) process of care (early detection, timely
initiation of treatment, prompt referral and follow-up, and accurate
measurement and diagnosis); (2) intermediate outcomes (reductions
in hospitalization, re-hospitalization, length of hospital stay, and
emergency department visits); and (3) ultimate outcomes (improved
symptoms, reduced disability, and reduced mortality/increased lon-
gevity as well as increased satisfaction). The empirical assessment is
based on the direction and weight of the evidence.
The extant data provide strong support for the contention that
telemonitoring of patients with CHF is likely to reduce mortality and
morbidity. The evidence is even stronger for the cost-effectiveness of
telemedicine interventions among persons with these chronic ill-
nesses. Significant associations have been found between tele-
medicine and reduced hospital admissions, shorter length of stays,
and reductions in emergency department visits. Hence, it may be
reasonably inferred that cost savings and health benefits would ac-
crue to both patients and providers from this intervention.
Significant reductions in ‘‘death and dependency’’ were associated
with telestroke interventions for persons suffering a stroke. Support
for this general conclusion derives from studies assessing event
timing from onset of symptoms, to diagnostic tests, to initiation of
thrombolytic treatment when indicated, and to referral when nec-
essary. Telestroke programs demonstrated accuracy in diagnosing
ischemic versus hemorrhagic stroke and in reducing time to defini-
tive treatment. Also impressive were the wide range and combina-
tions of telemedicine technologies used that uniformly resulted in
improvements in the diagnosis and management of stroke. It is im-
portant that these improvements were obtained across a wide variety
of settings involving patients in remote communities. Studies fo-
cusing specifically on ‘‘cost-effectiveness’’ were limited. Never-
theless, annual cost savings to hub-and-spoke hospital networks
were identified. More timely remote identification of stroke type and
simultaneous reduction of time to treatment are associated with re-
duced cost to both patient and provider, coupled with better health
outcomes and improved quality of life for patients.
The major issue addressed in assessing telemedicine’s impact on the
treatment of COPD focused on predicting, anticipating, preventing, and
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managing exacerbations in patients’ conditions. Although amenable to
treatment, these conditions adversely affect quality of life. A significant
decline in pulmonary function increases the risk of mortality, and its
management is costly. The major telemedicine intervention for COPD is
telespirometry (remote testing for lung function) along with monitoring
of heart rate, physical activity, and oxygen saturation. Perhaps in part
because of the nature of COPD, few studies incorporated mortality as an
end point. It is important, however, that telemedicine interventionswere
found to reduce acute exacerbations requiring change in medications,
hospitalizations, and re-admissions. Additionally, telemedicine inter-
vention was associated with improved rehabilitation and a decreased
need for urgent care from pulmonologists or the patients’ own GPs.
A FINAL COMMENT
With the wider dissemination of telemonitoring, we can expect more
patients with serious chronic illnesses to survive longer and to enjoy
better quality of life than in the pre-telemedicine era. Of course, in this
case, the law of ‘‘unintended consequences’’ may come into play. De-
laying mortality for older adults, as they live longer, is likely to lead to
increased use of health services, especially over the long run. None-
theless, the high cost of acute episodic care will be reduced through
timely intervention and substitution, and patients may be more likely to
avoid risky behaviors, thereby lowering overall healthcare expenditures.
Executive Summary
Concern with issues of inequitable access, uneven distribution of
quality, and cost inflation in healthcare has long historical roots. Yet, the
various policies and programs aimed at redressing them since the be-
ginning of the 20th century have met with limited success, as manifest
in their continuity and, in some instances, exacerbation. Although there
is no consensus on the most effective approaches to address these
problems, there is universal agreement regarding their serious impli-
cations for the health, well-being, and productivity of large segments of
the population, as well as the threat to the public purse.
Advanced applications in ICT in healthcare (referred to here as
telemedicine) were developed and tested with an eye to improve
healthcare access and quality while attempting to contain cost in-
flation. This technology has opened new vistas in connectivity,
clinical and shared decision making, system integration, and patient
empowerment, as well as organizational and operational efficiency.
Indeed, the need for the wider deployment of telemedicine systems
(also referred to as telehealth, e-health, mobile health, and connected
health) stems from a large and ever-expanding body of empirical
evidence that attests to their merit in addressing the issues of
healthcare access, quality, and cost. This is particularly notable in the
case of chronic diseases, which are leading causes of death, illness,
disability, and diminished quality of life. Together they also make up
the largest contributor to healthcare costs. It is estimated that over
50% of all adults have at least one chronic illness. It is important that
these diseases are amenable to telemedicine intervention.
A careful review of the published literature on telemedicine
management of three chronic diseases (CHF, stroke, and COPD) re-
veals inconsistencies in methodologies used and variations in out-
comes measured. We tried to reduce such variations by selecting only
RCTs or designs approximating an RCT and a minimal sample of 150
cases (with a few exceptions, which are noted). A separate section is
devoted to cost studies. Because the studies did not use a standard
methodological protocol, their respective findings and conclusions
must be viewed from the perspective of the design features that were
used, including research design, sample size, and the specific attri-
butes of the intervention itself, such as technological configuration,
provider mix, patient mix, program content, frequency, and duration
of the intervention. There were also variations in the measures of
outcome. Findings are presented in terms of the reported empirical
evidence on health outcomes, use of service, and cost.
FINDINGS RELATED TO HEALTH OUTCOMES
Among CHF patients, telemonitoring was significantly associated
with reductions in mortality ranging from 15% to 56% compared
with patients undergoing ‘‘usual’’ care. In only one study61 was
mortality higher among the telemonitoring group. However, this
exception may be accounted for by the fact that the study population
was composed of a very elderly and severely sick patient population
and other methodological issues. Conclusions from several studies
indicate ‘‘noticeable change (improvement) in health outcomes,’’
‘‘fewer episodes of health worsening,’’ ‘‘improved quality of life,’’ and
‘‘general improvement in clinical, functional, and quality of life
status.’’ In one robust study,54 no significant differences were ob-
served between the intervention and control groups in terms of
mortality and morbidity. Telemonitoring offers lesser benefits for
elderly patients with multiple health problems, especially when those
in ‘‘usual care’’ have ready access to appropriate care.
Telestroke provides an inherent advantage for stroke patients who
do not have ready access to stroke specialists. Prompt diagnosis,
initiation of treatment, supervision, and referral (when indicated) are
critical for a successful outcome, given a potentially debilitating, if
not fatal, disease. Except for the telephone-only intervention (with
poor sensitivity compared with video), the various modalities of
telestroke have been demonstrated to reduce mortality in the range of
25% during the first year after the event.
Only three COPD studies measured mortality outcomes. Two RCT
studies reported neutral findings, but one of these studies followed up
patients for only 1 week.123 An observational study found ‘‘some
positive benefits vis-a`-vis COPD mortality’’ 2 months after discharge
from the hospital.130 Likely positive effects of telepulmonology in-
clude fewer exacerbations in the disease and improvements in quality
of life and exercise capacity.
FINDINGS RELATED TO USE OF SERVICE
The majority of studies of telemonitoring for all three chronic
diseases reported lower hospital admissions and re-admissions,
length of stay, and emergency department visits. There were notable
exceptions, but in those instances the effects of telemonitoring were
neutral. One study121 found telepulmonology to result in cost shifting
in the outpatient setting (i.e., a decrease in demand for pulmonolo-
gists and an increase in demand for nurses).
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FINDINGS RELATED TO COST
The economic effects of telemonitoring have been measured or
examined in two ways: (1) changes in rates or volumes of hospital
admissions, re-admissions, length of stay, and/or emergency de-
partment visits and (2) cost-benefit analysis and cost-effectiveness
analysis of telemonitoring in terms of specified outcomes. In both
instances and with few exceptions, the evidence supports the eco-
nomic benefits of telemonitoring compared with usual care among
patients with CHF, stroke, and COPD.
Conclusions
There is an ever-growing and complex body of empirical evidence
that attests to the potential of telemedicine for addressing problems
of access to care, quality of care, and healthcare costs in the man-
agement of the three chronic diseases chosen for this review. Despite
some inconsistencies in methodologies, the preponderance of the
evidence produced by telemonitoring studies points to significant
trends in reducing hospitalization and emergency department visits
and preventing and/or limiting illness severity and episodes, result-
ing in improved health outcomes. It is hoped that this evidence would
be useful for policymakers, researchers, program developers, pro-
viders, payers, and the public at large.
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